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 ABSTRACT
BACKGROUND AND OBJECTIVES
 The aim of this study was to evaluate the effect of intravenous dexmedetomidine
on prolongation of  spinal anesthesia.
METHODS
 Study population comprised of 100 patients scheduled for abdominal/vaginal
hysterectomy under spinal anesthesia. 100 adult patients  classified as ASA 1 or 2
were  studied. Patients were randomly assigned to one of the two groups
 In Group-D patients received hyperbaric intrathecal bupivacaine anesthesia
3.5ml 0.5% (17.5 mg) and intravenous Dexmedetomidine 0.5micro grams/Kg
in10 ml  normal saline over 10 minutes after initiation of spinal block.
In Group C patients received hyperbaric bupivacaine anaesthesia 3.5 ml 0.5%
(17.5mg) and intravenous normal saline 10 ml over 10 minutes.
RESULTS
 The  time  for  the  motor  block  to  become  B0  was 243±17.0 minutes in the
study group  and  in  the  control  group  it  was  211.2±16.7 minutes The total time
for sensory level to reach S1 was 255±8.6in the study group while it was
210.8±33,1 in the control group. The time for two dermatome regression from the
maximal level was 125.2±17.5minutes  in the study group and 94.6±18.9 in the
control group. This proved the significant prolongation of motor block, sensory
block, sensory block to regress from the maximal level in the study group with a p
value of 0.001***.
CONCLUSION
Dexmedetomidine  in the dose of  0.5 microgram/kg  given as single intravenous
dose to patients  who underwent abdominal/vaginal hysterectomy under spinal
anesthesia significantly prolonged the duration of sensory and motor blockade and
also caused arousable sedation.
INTRODUCTION
Spinal  anesthesia  is  a  well  known technique  of  regional  anesthesia  and   is
always  considered  as a  safe  option  to general anesthesia when the surgical site
is located to the lower extremities,   perineum or lower  abdomen[1]. Spinal
anesthesia produces intense sensory, motor and sympathetic blockade with
significantly lesser concentration of local anesthetics when compared to other
modes of regional anesthesia. Although the operating site is anesthetized and the
patient cannot appreciate pain, he or she remains awake during the whole
procedure   which   contributes  to  mental   stress   ranging   from  mild  to  severe
depending on the patient’s mentality.
Spinal anesthesia has many advantages like low cost, reduced risk of
aspiration even in patients who are considered to be full stomach and  reduced
blood loss. There is relaxation of abdominal muscles  and this facilitates surgical
approach. The main limitation of spinal anesthesia is  that it is  limited in duration.
The patient’s  anxiety adds to the technical difficulties.
Usually spinal anesthesia with hyperbaric bupivacaine  lasts for 2 to 2.5
hours.[2]. To extend the duration of spinal anesthesia adjuvants like opiods,
epinephrine and  neostigmine  are added to  local anesthetics and instilled into the
subarachnoid space. These added substances have their own advantages and
disadvantages.
Sedation in  adequate dose  during  neuraxial block   alleviates the anxiety of
the patient[3].  When the  patient  is  relaxed  ,the  surgeon  finds  it  easy  to  operate[4].
Under sedation ,patients should be able to respond to command and maintain a
patent airway with minimal oxygen supplementation.
Two commonly used drugs for sedation   are propofol and midazolam.
Intravenous  propofol   in  the  dose  of    0.2to  0.3  mg/kg  is  used  for  sedation.  This
produces a rapid  decline  in the level  of consciousness. With a continuous
infusion of  propofol  both the cardiovascular  and respiratory function are
depressed to a considerable extent. The newer  water soluble benzodiazepine,
midazolam   given  in  the  dose  of  0.03mg/kg   has   a  quick   onset  of  action.  But,
recovery  is slow.
In day to day practice although we use midazolam and propofol  for sedating
patients, they are vulnerable to cause  significant  reduction  in blood pressure and
respiratory function. This effect can sometimes be deleterious to the patient. Hence
there has been always a search for the ideal sedative which can be used  to relieve
anxiety.
The newer drug Dexmedetomidine is a more specific alpha 2 adrenoreceptor
agonist. It  causes analgesia, sedation and sympatholysis. Food and Drug
Administration (FDA) approved the use of dexmedetomidine in 1999 for short-
term  sedation and analgesia (<24 hours) in the intensive care unit. It is becoming
very popular because it maintains hemodynamic stability   and does not cause
significant respiratory depression.
? 2-adrenergic receptor (? 2-AR) agonists have been  used in varied clinical
situations because of their actions which include sedation, analgesia, anxiolysis,
perioperative sympatholysis, cardiovascular stabilizing effects, reduced anesthetic
requirements, and preservation of respiratory function.
Many studies are available in the literature which prove the efficacy of
clonidine ,a first generation alpha2 agonist to prolong spinal anesthesia whether
administered  by intravenous or intrathecal route.[2][5] Clonidine is also known to
decrease the anesthetic requirements in general anesthesia[6] .
Dexmedetomidine being a second generation alpha2 agonist is more specific
for alpha2 receptors. Dexmedetomidine  acts on the locusceruleus area of brain
stem which is concerned with modulation of sleep and respiratory control. This
results in sedation without respiratory depression.
Dexmedetomidine has all the properties of an ideal sedative. There is a
hypothesis that by its actions in the substantia gelatinosa in the spinal cord (spinal
action)and locus ceruleus in the brain (supra spinal action) dexmedetomidine can
prolong spinal anesthesia. This is the basis of its antinociceptive action.[7]Studies
have been conducted to prove that dexmedetomidine when given intravenously or
intrathecally  prolongs the duration of spinal anesthesia. [8][9][10]
In  this   study  we  investigated  the  effect    of  a  single  intravenous  dose  of
dexmedetomidine on hyperbaric bupivacaine spinal anesthesia. In addition to
prolonging the duration of spinal anesthesia, dexmedetomidine causes a decrease
in stress response, heart rate and blood pressure  by lowering secretion of
catecholamines. This can be of great value in the perioperative period   during
which most of the vulnerable hemodynamic variations occur due to stress.
AIM OF THE STUDY
AIM OF THE STUDY
The main aim  of this study was to investigate the effect of  a single dose of
0.5micrograms/kg  of  dexmedetomidine administered intravenously over 10
minutes  after   initiation of neuraxial  block, on prolonging  duration of  sensory
and motor block in  hyperbaric bupivacaine spinal anesthesia. Proper approval
from the  Institutional ethical board  was obtained  and  the study was conducted
over a period of  six months.

OBJECTIVES
PRIMARY OUTCOME
Total duration of both sensory and motor blockade after hyperbaric
bupivacaine anesthesia   was studied.
SECONDARY OUTCOME
Grade of sedation
REVIEW OF LITERATURE
Aantaa , Kanto J,  Kallio A et al[11]  had done a study in patients undergoing
minor gynecologic surgery .  Nineteen   women who  had been posted for
dilatation and curettage of the uterus were given dexmedetomidine in the dose of
0.5 micrograms/kg fifteen minutes before induction  and another set  of 20 patients
received  saline  in the same frame. Anesthetic induction  was given  with
thiopental. The maintenance  of anesthesia was with N2O/O2 (70/30%) and with
incremental doses of   thiopentone sodium .  In their study they had observed that
“The  total amount of thiopental required  to maintain patient in a good plane of
anesthesia for performing the procedure was reduced by  approximately 30%, in
the group that had received  dexmedetomidine”.  They had observed that the
recovery from anesthesia was much better with dexmedetomidine as measured by
the visual analogue scale. They measured the concentration of norepinephrine and
found a 56%reduction in  concentration of nor epinephrine  because of the
sympatholysis caused by dexmedetomidine.   They had observed moderate
decrease in systolic and diastolic blood pressure after dexmedetomidine
administration. The authors concluded that  “Premedication with dexmedetomidine
decreased thiopental anesthetic requirements and also improved the recovery from
anesthesia with no serious hemodynamic compromise”.
Khaled Taha[12]   had done a study in 60 patients evaluating analgesic
,sedative and hemodynamic effects of Dexmedetomidine following major
abdominal surgeries. It was a randomized ,double blinded comparative study with
morphine. All surgeries were under general anesthesia. Twenty minutes before
surgery random allocation of groups was done. One group received
dexmedetomidine as intravenous infusion 4 microgram/kg/hr for 15 minutes and a
maintenance dose for 3 hours at the rate of 0.4 microgram/kg/hour. Another group
received a single dose of  morphine 0.07mg/kg. All patient received patient
controlled analgesia with morphine. They concluded that “There was significant
decrease in the total PCA morphine in the dexmedetomidine group”. The author
had emphasized  that  cardiovascular effects of  dexmedetomidine  could be
beneficial in patients with ischemic or non ischemic heart disease.   The authors
had concluded that “The cardiovascular protective profile and the lack of
respiratory depression makes dexmedetomidine  a suitable drug for post operative
analgesia after major abdominal  surgeries”.
Kanazi  GE,  Aouad  MT,  Jabbour-Khoury  SI  et  al, [8]   did  a  prospective,
double-blinded  study on  60 patients  posted for transurethral resection of prostate
or bladder tumor under spinal anesthesia. Patients were  allocated to  three groups
randomly. Patients in   Group 1 were given  hyperbaric bupivacaine 12 mg.
Patients  in  group  2    were  given   12  mg  of  bupivacaine  supplemented  with
dexmedetomidine  3 microgram . Patients in  group 3 were given  12 mg of
bupivacaine supplemented with  clonidine 30 microgram. .The onset time for peak
sensory and motor levels, and the sensory and motor  block regression time were
recorded.. The authors  concluded that  “Dexmedetomidine (3 microgram) or
clonidine (30 microgram), when added to intrathecal bupivacaine, produces a
similar prolongation in the duration of the motor and sensory block with preserved
hemodynamic stability and lack of sedation”.
Murat  Teikin,  kati  I,Yakup  et  al[13] had done a double-blind, prospective
study in  60  patients classified as American Society of Anesthesiologists grade I to
II  who  were   posted  for   lower  abdominal,  anorectal,  lower   extremity  surgery
under  spinal  anesthesia.  Patients    were  assigned  to  1  of  2  groups.  All  patients
received  prilocaine 2% for spinal anesthesia. After 10 minutes patients in  group 1
received a loading dose of dexmedetomidine 1 ?g/kg IV, followed by a
maintenance dose of 0.4 ?g/kg / h for 50 minutes; group 2 (control) received the
same  amount  of  physiologic  saline  in  the  same  time   schedule.  Hemodynamic
parameters were also assessed. They  concluded that “Intravenous
dexmedetomidine significantly prolonged the duration of spinal anesthesia and
provided a significantly higher level of sedation compared to placebo   and was
well tolerated  by  all patients.”
Menon DV, Wang Z, Fadel PJ, Arbique D, [14] et  al,  had  done  a  study   to
determine whether cocaine's sympathomimetic actions could  be reversed by
dexmedetomidine which is a alpha2 agonist. They had  conducted  a study  in  22
healthy cocaine-naïve humans. Intranasal cocaine [2 mg/k g] was given to all  the
subjects ,and then they were divided into two groups. One group received
intravenous dexmedetomidine and the other group received intravenous saline. The
parameters studied were sympathetic neuronal activity (SNA)measured by
microneurography, skin vascular resistance as measured by laser doppler
velocitometry ,heart rate and mean arterial pressure. They had observed that in the
group that received dexmedetomidine there was no increase in sympathetic
neuronal activity ,skin vascular   resistance heart rate blood pressure.
Dexmedetomidine  abolished these increases, whereas intravenous saline was
without effect. The authors had concluded that  “Dexmedetomidine was effective
in blocking  sympathomimetic actions of cocaine”.
Al-Mustafa MM, Badran IZ, Abu-Ali HM, et al,[10] did a study in 48 patients
who underwent  transurethral resection of prostate, trans urethral resection of
bladder tumor  under spinal anesthesia. In that study they had randomly allocated
patients into 2 equal groups after spinal isobaric bupivacaine 12.5mg. One group
received intravenously a loading dose of dexmedetomidine 1 microgram/kg over
10 minutes and a maintenance of  0.5 micrograms /kg/hour. Another group
received normal saline in the same frame. The regression time to reach S1 sensory
level, Bromage scale 0, hemodynamic changes during surgery and level of
sedation were studied.   In their study they had concluded that “Dexmedetomidine
given by intravenous administration prolonged the sensory and motor blocks of
bupivacaine spinal anesthesia with good sedation effect and hemodynamic
stability”. They had assessed motor level using Bromage scale, sedation using
Ramsay sedation scale and time for regression to S1 dermatome.
Kaya FN, Yavascaoglu B, Turker G et al [9]had done a study   to compare
intravenous dexmedetomidine with midazolam and placebo on spinal block
duration, analgesia, and sedation in patients undergoing transurethral resection of
the prostate. In this double-blind randomized placebo-controlled trial, 75 American
Society of Anesthesiologists' I and II patients were divided into 3 groups .One
group  received dexmedetomidine 0.5 microgram / kg, Second group received
midazolam 0.05 mg / kg and the third group received  saline intravenously before
spinal anesthesia. All patients received bupivacaine 0.5% 15 mg  intrathecally. In
their study they had observed that the duration of motor block was similar in all
groups. Dexmedetomidine also increased the time to first request for postoperative
analgesia (P < 0.01 ) and decreased analgesic requirements. The maximum
Ramsay sedation score was greater in the dexmedetomidine and midazolam groups
than in the saline group (P < 0.001). They had concluded that “Intravenous
dexmedetomidine, but not midazolam, prolonged spinal bupivacaine anesthesia”.
Ok  HG,  Baek  SH,  Baik  SW,  Kim  HK et al, [15] had  done  a  study  to
determine  the  optimal dose of dexmedetomidine that can be given for  sedation
during spinal anesthesia. In their study they had emphasized on the need of
sedation in patients under spinal anesthesia.  They had selected one hundred and
twenty eight patients, aged 20-70 years who underwent surgery under spinal
anesthesia. After   spinal anesthesia was initiated  with hyperbaric bupivacaine (13
mg),  dexmedetomidine (1 µg/kg)as loading dose intravenously  was administered
over  10 min for all the patients .After that patients were divided into 3 groups  and
followed by the maintenance infusion  which differed  in each group. Group A
comprising of 33 patients received  normal saline, Group B  comprising of 35
patients received dexmedetomidine in the dose of 0.2 µg/kg/hr, and Group C with
39 patients received dexmedetomidine in the dose of  0.4 µg/kg/hr. Heart rate,
blood pressure, and the bispectral index score (BIS) were  monitored and noted
during the operation. In the recovery room, modified aldrete score (MAS) was
measured. They had concluded that    “The loading dose (1 µg/kg/10 min) of
dexmedetomidine was sufficient for sedation  for surgery of less than 60 min done
under  spinal  anesthesia.  This  should  be   followed  by   a  maintenance  dose   of
dexmedetomidine  (0.2 µg/kg/hr)  for surgeries which last for  90 min”.
Annamalai A, Singh S, Singh A, Mahrous DE et al, [16] had  done a study in
ninety   ASA1 or 2 patients posted for surgeries below umbilicus under spinal
anesthesia. Patients  had been double blind randomized in to three groups. One
group received normal saline 10 ml over 10 minutes  before  spinal anesthesia.
Second group received dexmedetomidine 1 microgram/kg through intravenous
route 10 minutes before spinal anesthesia. Third group received dexmedetomidine
1 microgram/kg via intravenous route 10 minutes after spinal anesthesia. All the
patients  had  been advised to take  tablet alprozolam 0.25mg and tab ranitidine
150 mg on the previous night and on the day of surgery. They   concluded that
dexmedetomidine through intravenous route prolonged spinal “sensory blockade
in both the groups irrespective of  the timing whether it  was given before or  after
spinal anesthesia. The onset of post operative pain was delayed in the group which
received dexmedetomidine”.  The authors further concluded that “The patients in
the dexmedetomidine group needed lesser doses of post operative analgesic than
the other group”.
Jia Song, Woong-Mo Kim et al,[17] had done a study in 45 ASA1 or 2
patients who underwent surgery under spinal anesthesia. In that study they had
given dexmedetomidine in three different doses to evaluate the hemodynamic
changes and their main aim was to get the optimal dose of dexmedetomidine. All
patients were given a loading dose of dexmedetomidine 1 microgram/kg. Then the
patients were divided randomly into one of the 3 groups for maintenance dose.
One group received dexmedetomidine in the dose of 0.25 microgram/kg/hr, second
group received dexmedetomidine in the dose of 0.5 microgram/kg /hr and the third
group received dexmedetomidine in the dose of 0.75microgram/kg/hr .They had
clearly stated  that patients were able to remain calm after sedation with
dexmedetomidine. They had stressed on the  need of adequate sedation if the
advantages of spinal anesthesia are to be fully appreciated. In their conclusion  Jia
song et al had stated about the incidence of hypotension as the dose increased.
They had emphasized on the fact  that  “To  minimize the  risk  of  hemodynamic
instability   a   maintenance  dose  of 0.25micrograms/Kg/h r may be most
appropriate”.
SS Harsoor, D Devika Rani, Bhavana et al[18] did a study  to determine  the
effects of intravenous dexmedetomidine on sensory, motor, haemodynamic
parameters and sedation after spinal anesthesia.  50 patients posted for infra
umblical and lower limb surgeries under  neuraxial blockade  were selected and
divided into 2 groups. Group D received dexmedetomidine in the dose of 0.5
mcg/kg  intravenously bolus over 10 min prior to spinal , followed by an infusion
of dexmedetomidine 0.5 mcg/kg/h for the duration of the surgery. Group C
received similar volume of normal saline infusion. They  concluded that
“Administration of intravenous dexmedetomidine during spinal anesthesia
hastened the onset of sensory block and prolonged the duration of sensory and
motor block with satisfactory  arousable  sedation”.
Abdallah FW1, Abrishami A, Brull et al, [19] had  evaluated whether
intravenous  dexmedetomidine can prolong the duration of sensory block
associated with spinal  anesthesia.  The parameters assessed by the authors  were
duration of sensory and motor block,  onset  time for sensory and motor block,
postoperative pain scores, time to first analgesic request, total analgesic
requirement   and   side  effects.  A  total  of  364  patients  were  analyzed  from  7
randomized controlled trials. The authors had concluded that “When intravenous
dexmedetomidine accompanied spinal anesthesia, sensory block duration was
prolonged by about 34% , motor block duration was prolonged by about  17%, and
time to first analgesic request was increased by 53% with a significant p value”.
They had stated that there was increased incidence of bradycardia in
dexmedetomidine group. They had concluded that “Intravenous dexmedetomidine
prolonged  the duration of sensory block, motor block, and time to first analgesic
request associated with spinal anesthesia.”
Seung Hwan Jung et al[20] had  done  a   study  in   sixty  adult  patients  who
were scheduled for lower extremity surgery under spinal anesthesia. Patients were
randomly allocated  to one of three groups and administered hyperbaric intrathecal
bupivacaine 12 mg. After 5 minutes of  spinal anesthesia, patients in groups 1
were administered  normal saline 10 ml intravenously, patients in group 2 were
given intravenous dexmedetomidine 0.25 microgram/kg, and  the third group
received   dexmedetomidine i.v  0.5 microgram/kg over 10-minutesThey
concluded that “The single-dose intravenous dexmedetomidine 0.25–0.5 ?g/kg,
administered 5 min after intrathecal  hyperbaric bupivacaine, improved the
duration of spinal anesthesia without significant side effects”. They stated that this
effect on spinal anesthesia could be seen  even when dexmedetomidine is
administered  several minutes after spinal anesthesia.
Reddy VS, Nawaz Ahmed Shaik and Venkatsiva Janga[21]  had compared
the efficacy of intravenous dexmedetomidine   with clonidine and placebo on
spinal blockade duration, analgesic effect post operatively and sedation in patients
undergoing surgery under bupivacaine neuraxial block. 75 patients of the ASA  I
or II, scheduled for orthopedic lower limb surgery under spinal anesthesia, were
randomly divided  into three groups  each group consisting of 25 patients. Group 1
received dexmedetomidine 0.5 microgram/kg/hr, group 2 received clonidine 1.0
microgram/kg/hr and placebo group 3 received 10 ml of normal saline
intravenously before subarachnoid anesthesia with 15 mg of 0.5% hyperbaric
bupivacaine They  concluded that  “Premedication with intravenous
dexmedetomidine was better than  clonidine for intraoperative sedation and
postoperative analgesia during  spinal anesthesia with hyperbaric bupivacaine”.
Dinesh CN, Sai Tej NA, Yatish B et al, [22]  had done a study  to  evaluate
the effects caused by  intravenous dexmedetomidine on spinal anesthesia with
0.5% of hyperbaric bupivacaine. One hundred  patient posted for elective surgeries
under spinal anesthesia were randomized into two groups of 50 each. After
subarachnoid block with  0.5% hyperbaric bupivacaine 3 ml, patients in
dexmedetomidine group were given  a loading dose of  dexmedetomidine  1
microgram/kg of  intravenously  over 10 min followed by a drip in the  dose of 0.5
microgram/kg/hour  as maintenance  till the end of surgery, whereas patients in
control group  received an equivalent quantity of normal saline. In their study they
concluded that “Intravenous dexmedetomidine  prolonged the duration of sensory
and motor block of  hyperbaric bupivacaine spinal anesthesia”. The authors had
observed that the occurrence of bradycardia was higher when intravenous
dexmedetomidine was used  in  bupivacaine spinal anesthesia.
Park SH, Shin YD, Yu HJ, Bae JH, et al[23]  had compared the effects caused
by  two different  doses of intravenous dexmedetomidine in elderly patients during
spinal anesthesia.  They had selected 45 elderly patients (? 60 years) classified as
ASA1 or II who were posted for transurethral resection of the prostate or
transurethral resection of the bladder tumor  and the patients  were divided
randomly into three treatment groups. The group  1 received  dexmedetomidine  in
the dose of 0.5 µg/kg while the second  group received dexmedetomidine 1 µg/kg
intravenous injection over 10 min before anesthetic induction. The Control group
received  normal saline. Comparison was done  regarding the maximum sensory
block level, extension of anesthesia, degree of motor block, sedation level and
complications. They had concluded that “There was not much of difference in the
groups on achieving the maximum level of sensory block and motor block. But the
total time of sensory block was significantly longer in group which received
dexmedetomidine 1microgram/kg than in the control group”. There was significant
increase in bradycardia in the patients who received dexmedetomidine. No
complications such as hypotension, nausea, tremor, and hypoxia was reported by
them .
DEXMEDETOMIDINE –PHARMACOLOGY
Dexmedetomidine is the dextrorotatory S-enantiomer of medetomidine,
which is widely used in veterinary practice[24].
Chemically, Dexmedetomidine is (S)-4-[1-(2,3-dimethylphenyl) ethyl]-3H-
imidazole
CHEMICAL FORMULA   is   C13H16N2[11][12]
 Structure of   dexmedetomidine
Clonidine, the first generation alpha 2 agonist has been in use for many
years. It is used as an antihypertensive by oral route. When given intrathecally, it
prolongs the duration of spinal anesthesia[2]. Intravenously it decreases anesthetic
requirements. Dexmedetomidine  is a newer drug  in the same group and has many
advantages when compared to clonidine.
Differences  between clonidine and dexmedetomidine[25][26]
CLONIDINE DEXMEDETOMIDINE
It was first synthesized in 1960s Dexmedetomidine was first
produced  in 1980s
Started to  use clinically  as
antihypertensive  in 1966.
Approved for clinical use as
analgesic and sedative in 1999.
Alpha2;Alpha1 receptor binding
ratio is 220:1.
Alpha2;Alpha1 receptor binding
ratio is 1620:1
Acts  as  a  partial  agonist  at  alpha
receptor.
Acts  as  a  full  agonist  at  alpha
receptor.
Octanol /buffer partial coefficient
is 0.8.
Octanol /buffer partial coefficient
is 2.8.It is 3.5 fold more lipophilic
than clonidine.
Plasma half life is 9-11.5 hours. Plasma half life is 2-2.25 hours.
It is 50% bound to proteins. It is 94%bound to proteins.
Elimination half life is 8 hours. Elimination half life is 2 hours.
Distribution half life >10 minutes. Distribution half life is 5 minutes.
It has been proved that there is
50% reduction in MAC of
inhalational agents when clonidine
is used.
It has been proved that there is
90% reduction in MAC of
inhalational agents when
dexmedetomidine  is used.
ALPHA 2 ADRENORECEPTOR
Schematic  representation  of  alpha2
Adrenoreceptor
The prime sympathetic neurotransmitter nor adrenaline and the most
important  adrenal medullary hormone adrenaline mediate their central and
peripheral actions through a special type of  receptors called adrenergic receptors.
Adrenergic receptors are abundantly present in nearly all peripheral tissues
and in the neurons of the  central nervous system.[27] There are three types of
adrenergic receptors. They are alpha1,alpha2,and beta receptors.  These
adrenergic receptors  are one among  cell surface receptors that arbitrate their
actions through guanine nucleotide binding  proteins [G-Proteins][26].
Alpha2 receptors are again subdivided into 3 subtypes
alpha2A,alpha2B,alpha2C[28].They have individual patterns of tissue distribution in
the two types of nervous system.
ALPHA 2A are  found  in Locus ceruleus of  brain,
nor adrenergic cell body regions,
spleen, pancreas,
kidney, blood vessels, urethra,
thrombocytes.
ALPHA2B are found in Kidney, placenta, liver smooth
muscle of blood vessel ,thalamus
ALPHA2C are  found  in Central nervous system
There are two mechanisms of action of alpha2 receptor agonists. When  the
alpha2 receptor is  activated, calcium entry into the nerve terminal is decreased and
this action is responsible for  the inhibitory effect on  catecholamine
secretion[24][29]. N-type voltage-gated calcium channels  are directly involved in
this particular action. G0 proteins mediate this action.
Alpha2 receptor stimulation also  inhibits the enzyme adenylate cyclase.
Adenylate  cyclase is the key enzyme which is  responsible for the production of
3,5-cyclic adenosine monophosphate . The net result  is decreased  availability of 3
5 cyclic AMP, which is a second messenger.
Specific cyclic AMP-dependent kinases alter the  phosphorylation status of
target proteins. Due to decreased levels of 3,5,cyclic AMP ,  major alterations
occur in the ion channel activity[26].  This  results  in  hyperpolarization  of  the cell
membrane. Thus neuronal firing is suppressed to a great extent. Activation of  G1-
protein gated potassium channels on the cell surface causes hyperpolarization of
membrane  which in turn  decrease  the firing rate of excitable cells in the central
nervous system.
Activation of the  ?2adrenoceptor present in the presynaptic regions leads to
the reduction in the release of  neurotransmitter  nor epinephrine. Because of the
decreased concentration of the prime neurotransmitter, cell signals are not
propagated.  This leads to decreased sympathetic activity  and reduction in blood
pressure and heart rate.
Dexmedetomidine, a single drug can produce all these effects and  thus
avoiding much complicated  multiple drug therapy. In multiple drug therapy many
drugs belonging to  different classes are usually given to produce all these
beneficial effects.
Till date ,there is no clear mention of the mechanism by which alpha 2
agonist cause analgesia. Most likely postulated mechanisms include supraspinal
action in the locus ceruleus  and spinal action in the substantia gelatinosa that
modulate the transmission of nociceptive signals in the central nervous system[29].
Drugs may perform action  at any of these sites  resulting in analgesia.
By  the  result  of   all  these  actions   neither  the  nerve  can  fire  nor   it  can
propagate  signal to the neighboring cells. Ultimately, this results in   analgesia by
central, spinal and peripheral mechanisms. The net  result is a considerable
reduction in the stimulation and propagation of nervous signals.
Action in the brain stem
Alpha2 receptors are  present   in highest densities in the locus ceruleus[12]
the chief  noradrenergic nucleus in the brain . The locus ceruleus is  one of the
important  centers  which control vigilance. The hypnotic and sedative effects of
alpha2 adrenergic receptor is due to the action on the locus ceruleus [26] [29].
The locus ceruleus is  also the place  of origin for the descending
medullospinal noradrenergic pathway , which is mainly involved in  nociceptive
transmission. This may be the reason for the anti nociceptive action of
dexmedetomidine.
The  ratios  of  ?2??1 activity is 1620:1 for dexmedetomidine and  220:1 for
clonidine. Therefore dexmedetomidine is a more suitable sedative and analgesic
agent than clonidine.
Spinal action of dexmedetomidine
Besides actions in the locus ceruleus of the brain stem, dexmedetomidine
causes  direct  stimulation  of     alpha2  receptors   in  the  spinal  cord.  The   alpha2
receptors are found in   abundance in  the substantia gelatinosa of the   dorsal horn
of the spinal  cord .On stimulation ,   these receptors inhibit  the firing of   neurons
accountable for nociception  perceived  by A? type  and C type  fibers [10][24][25][29].
Release of  substance P  is also inhibited.  This spinal mechanism is responsible for
dexmedetomidine  action   when  used  epidurally  and   when  administered   as   an
intravenous  drug .
Dexmedetomidine causes sedation  which resembles  physiological sleep
without causing respiratory depression.
Diagram Showing Physiological Response To Alpha2     Receptor Stimulation
Type of receptor Physiological  functions    and  responses  of
alpha receptors
Alpha 2A Presynaptic inhibition of neurotransmitter
release
Sedation and anaesthesia
Analgesia
Bradycardia and hypotension
Regulation of blood glucose and insulin
homeostatasis
Hypothermia
Inhibition of epileptic seizures
Decrease in intraocular pressure.
Inhibition of gastrointestinal motility
Alpha2B Vascular smooth muscle contraction
Hypertension
Placental angiogenesis
Alpha2C Presynaptic inhibition of catecholamine
release.
Modulation of motor behavior, vascular
smooth muscle contraction, Controlled
balance of dopamine and serotonin release in
the brain.
Pharmacokinetics  of  Dexmedetomidine
Absorption
Dexmedetomidine is  not orally active. The conventional route of
administration of dexmedetomidine is intravenous route. Dexmedetomidine  shows
good bioavailability when administered via  other routes  such as intranasal,
intramuscular, buccal,  sublingual, intragastric,  neuraxial,  regional,
intraarticular[24].
Distribution
In elimination phase the half life is 2-3 hours. The steady state volume of
distribution is 118 liters.
Protein binding
Dexmedetomidine is 94%protein bound. Hepatic impairment slightly
decreases the fraction bound to plasma proteins. In vitro  studies conclude that
dexmedetomidine does not displace phenytoin, warfarin, propanolol, theophyline,
digoxin from plasma proteins. Pharmacokinetics of   dexmedetomidine  does not
change with age, sex or in patients with renal failure[26].
Metabolism
DEX undergoes  (> 95%) biotransformation in liver into  inactive
metabolites. Direct N-glucuronidation is the main pathway of metabolism and
glucuronides are the important circulatory and urinary metabolites of
dexmedetomidine[24]. Hydroxylation and oxidation are the minor pathways.  It is a
must  to decrease the dose of dexmedetomidine  in patients with hepatic failure,
because  the half  life is prolonged in  hepatic failure .  The half life of
dexmedetomidine is 7.5 hours in hepatic failure whereas the elimination half-life
in healthy patients is approximately 2 hours.
In clinical doses ,dexomedetomidine  acts as a decongestant and as an
antisialagogue. It also has  antishivering and antiemetic effects. Added benefits of
dexmedetomidine include less respiratory depression when compared to other
drugs  with additional benefits of  cardioprotection, neuroprotection  and
renoprotection.
Adverse Effects
The commonly seen side   effects of dexmedetomidine are  bradycardia,
hypotension  and  dry mouth. Both bradycardia and hypotension respond promptly
to anticholinergics and vasopressors respectively.
Transient hypertension  is seen when given in large doses( due to peripheral
alpha2 B receptor   stimulation). Other reported side effects include nausea,
vomiting,  atrial fibrillation, pyrexia, chills, pleural effusion,  pulmonary edema,
atelectasis, hyperglycemia, hypocalcaemia, acidosis. After administration for more
than 24 hours as an infusion , sensitization and up regulation of receptors occur.
After abrupt discontinuation, a withdrawal syndrome of nervousness, agitation,
severe headaches, and emergency hypertensive crisis can occur[26].
Dexmedetomidine is contraindicated  in patients with advanced heart block
and ventricular dysfunction. FDA has classified it as a category C risk in
pregnancy. Hence the drug should be used with  caution in  pregnancy.

PHARMACODYNAMICS                                                                Effects on the
respiratory & cardiovascular system;
Activation of alpha 2 receptors leads to dose dependent reduction in
catecholamine level (up to 89%)[26].Due to  inhibition of sympathetic medullary
vasomotor center, bradycardia and hypotension occur.
In the respiratory centre  alpha2 receptors do not have any active  role and
so, dexmedetomidine  (up to 8 nanogram/ml), has minimal effects on the
respiratory system[24]. Hence, dexmedetomidine does not cause respiratory
depression.
Dexmedetomidine does not have any direct action on the myocardium[26].
After administering it rapidly in a  larger dose (>1 microgram/kg),  a biphasic
response on BP is seen.   There is an initial short hypertensive phase mediated by
peripheral alpha2B adrenergic receptor stimulation. Subsequent hypotension is
mediated by presynaptic ? 2A   adrenergic receptors. The direct action on the
peripheral vascular smooth  muscle  causing usually  lasts  for 10 minutes.
Dexmedetomidine causes  dose dependent decrease in the vasoconstriction
and shivering thresholds.
The postulated neuro protective action of dexmedetomidine
Dexmedetomidine reduces cerebral blood flow and cerebral metabolic
requirement  of  oxygen  .  There  are  many  studies  which   suggest  that
neuroprotective action is achieved by   reducing the levels of circulating and brain
catecholamines[26]. Thus it causes balancing  of the ratio between cerebral oxygen
supplies and demand . It reduces excitation levels, and improves the perfusion in
the ischemic penumbra[26]. It reduces  glutamate  levels  responsible for brain  cell
injury. This suggests the application of dexmedetomidine in head injury patients to
enhance cerebral perfusion.
The postulated renoprotective action of dexmedetomidine
Its renoprotective effects include  inhibition of renin release, increased
glomerular filtration, and increased secretion of sodium and water in the kidney.
These actions  are  probably mediated through  peripheral alpha2 receptors.
Antagonism of actions by Atipamezole
After continous infusion is stopped, dexmedetomidine  has a rapid and
predictable offset of action. Though not orally active, Atipamezole[30](antisedan) is
considered  to be an effective antagonist for reversing psychomotor  disturbance
and vigilance caused by dexmedetomidine.  Both dexmedetomidine and
Atipamezole  show  linear  pharmacokinetics  .    The  elimination  half-lives  of  the
two drugs is approximately  2 hours.  This is a clear benefit while considering the
promising clinical applications for long term use of dexmedetomidine  in  intensive
care unit.Any adverse effect can be countered by Atipamezole.
Clinical actions of dexmedetomidine
Centrally mediated   actions of dexmedetomidine
? Bradycardia and hypotension
? Sedation,  anxiolysis ,hypnosis
? Analgesia
Peripherally   mediated actions of dexmedetomidine
? Decrease of GI secretions, salivary secretion and decreased  gastro
intestinal  peristaltic movement.
?  Contraction of smooth muscle including blood vessels .
? Renin release is reduced by the inhibition of rennin angiotensin system.
Glomerular filtration rate (GFR) is increased.  Sodium excretion and water
excretion is enhanced. All these effects contribute to the diuretic effect of
dexmedetomidine.
? Significant reduction in  intra-ocular pressure
? Decreased release of insulin from the pancreas .
? Reduced  platelet aggregation
?  Shivering threshold is decreased approximately by 2ºC.
Clinical  Applications of dexmedetomidine
Peri-operative uses of dexmedetomidine
1.Attenuation  of  intubation  response
Dexmedetomidine decreases  stress response to tracheal
intubation/extubation when given in the dose of 1 microgram /kg with lesser doses
not being effective. It has analgesic sparing effect which lasts up to 24 hour[31].
2.As an adjuvant to GA
Dexmedetomidine  boosts the anesthetic effects of all anesthetic agents
despite the method of administration (intravenous, volatile or regional block).   It
has minimum alveolar concentration (MAC) reducing  and opioid sparing
 properties, which results in decreased use  of  inhalation anesthetics  and
opioids[32][33].
The reduction in myocardial oxygen demand  and rate pressure product
reduce myocardial ischemia and infarction which is very beneficial for cardiac
patients. When used  in obstructive sleep apnoea and in  morbidly obese patients, it
does not cause any cardio-respiratory depression and  helps  in  faster,
neuromuscular  recovery[34]. In literature search, case reports  are available stating
the use of  dexmedetomidine  as an anesthetic adjuvant intraoperatively  in
reducing episodes of abrupt  hypertension that  occurs  during manipulation of the
tumor in  surgery for pheochromocytoma .
3.As an agent for producing  Controlled hypotension
In the literature there are many studies  which say that dexmedetomidine  is
equally potent as  remifentanil  and esmolol in controlled hypotension application.
The parameters studied were intraoperative bleeding, preoperative hemodynamics,
lactate levels[24].
4.As an adjuvant to regional anesthesia
Researchers are doing intense search to find an  ideal adjuvant to regional
anesthesia .  The alpha 2 adrenergic agonists, in particular dexmedetomidine has
both analgesic and sedative actions.  3 ?g DEX and 30 ?g clonidine are equipotent
intrathecally. The addition of 5 ?g of intrathecal  dexmedetomidine  prolonged the
post-operative analgesic effect of ropivacaine by 8 hours[25].
5.As an adjuvant in peripheral nerve block
Dexmedetomidine (in the dose of 0.5 microgram/kg)when added to
bupivacaine in nerve blocks prolongs the duration of sensory block,  and decreases
tourniquet pain.
6. The role of dexmedetomidine in Cardiac anesthesia-
In American Heart Association (AHA) guideline 2002  ?2-adrenoceptor
agonist has been mentioned  as a grade IIb agent .  They are particularly of use in
situations  when   ? –blockers  are  contraindicated.    In  the  human  physiology
hemodynamic, sympathetic activity and renal function are closely interrelated.
Dexmedetomidine induced sympatholysis might attenuate harmful hemodynamic
events  responsible for deterioration of renal function  in patients undergoing
elective CABG with extracorporeal circulation[24].
7. The role of dexmedetomidine in Neuroanesthesia-
Anesthesia for awake craniotomy which needs cooperation of patients
presents a challenge to the anesthesiologist. Common  side effects  associated with
conventionally used neuroleptanalgesia are drowsiness,  respiratory depression,
agitation and intra operative seizure.  Using dexmedetomidine we can achieve  a
level of sedation and analgesia  to complete the neuropsychiatric testing for
electrocorticography ,for  the mapping of the cortical language area, for bone flap
removal, and  to perform an awake tumor resection [35].
8. The role of dexmedetomidine in monitored anesthesia care
Dexmedetomidine is an ideal agent for  many  procedures like fiberoptic
bronchoscopy, ophthalmic  procedures ,head and neck procedures, ,vascular
surgeries and dental procedures. Dexmedetomidine  provides better patient
satisfaction, less respiratory depression and less opiod requirements. Intraocular
pressure is decreased by dexmedetomidine which is an added advantage in
ophthalmic procedures. Intravenous dexmedetomidine in the dose of
0.6microgram/kg prevented the rise of intraocular pressure after suxamethonium.
9.As  Post operative analgesic
Its wide safety margins and respiratory function preservation allows
continued use of dexmedetomidine in extubated  patients. It decreases the
incidence of nausea and vomiting  postoperatively. Dexmedetomidine when added
to morphine in patient controlled analgesia  has been  proved to increase post
operative analgesia .
10. The role of dexmedetomidine in Intensive care unit
Sedation plays an important role in intensive care. The sleep induced by
dexmedetomidine mimics  normal sleep and  this is an  advantage during weaning
from mechanical ventilation.
Reduced stay in intensive care unit, decreased duration of ventilation,
haemodynamic stability and reduced agitation are the proven advantages of
dexmedetomidine. Dexmedetomidine need not be stopped and the sedation can be
maintained following tracheal extubation[36, 37].   Dexmedetomidine    is  an
alternative in patients developing  tolerance to opiods.
COMPARISON OF  SEDATIVES COMMONLY USED IN ICU
11.The role of dexmedetomidine in pediatrics
We can avoid unnecessary needle pricks  and  reduce the dose of opiods  by
using  dexmedetomidine  through  noninvasive  routes                      (intranasal,
buccal). The pharmacokinetics of dexmedetomidine  in infants and children is
more or less similar to that in adults.  In pediatrics the main upcoming role of
dexmedetomidine is to  prevent emergence delirium [36][37].  In  children,  it is used
in  various applications including procedural-sedation, sedation for mechanical
ventilation,  for preventing emergence delirium. Dexmedetomidine via intravenous
route or intramuscular  route has been used  to sedate children for procedures
without stimulation like MRI and CT scan. In children the dose  required for bolus
is 2to3 microgram/kg and for infusion is 2 ?g/kg/hour.   The combination of
dexmedetomidine  and ketamine makes pharmacologic sense as the two
medications have the potential to balance the hemodynamic and adverse effects
which make both a very effective combination.  Khaled Al Zaben et al had
reported the use of dexmedetomidine (5-10 ?g /kg/h) as the main anesthetic ,
supplemented by incremental propofol dose (100 ?g/kg/min)for three  children
with tracheomalacia[24].
12.The role of dexmedetomidine  in Obstetric anesthesia
In view of its high lipophilic nature ,dexmedetomidine is retained in the
placental tissue and this results in  less foetal transfer and a reduced incidence of
fetal bradycardia.  Continuous intravenous dexmedetomidine  infusion is being
used as an adjuvant to  opioids in labour analgesia[24].  Dexmedetomidine has an
antinociceptive effect to visceral pain.   Dexmedetomidine also  provides
hemodynamic stability, anxiolysis. Dexmedtomidine causes stimulation of uterine
contraction which is a beneficial effect  in parturient  mothers.
Caution about loading dose
Most of the adverse events associated with use of dexmedetomidine  occur
during or briefly after loading of the drug. Multiple studies have demonstrated that
by omitting or reducing the loading dose, adverse effects can be
reduced.  Although, avoiding the loading dose may prevent  erratic hemodynamic
effects ,it may cause delay in onset of action and time to reach    steady state.
BUPIVACAINE IN  SPINAL  ANESTHESIA
Basic pharmacology of bupivacaine;
Molecular Formula: C18H28N2O
Average mass: 288.427704 Da
Chemical  name;
(2S)-1-Butyl-N-(2,6-dimethylphenyl)-piperidinecarboxamide
Chemical structure;
Bupivacaine is a long acting spinal anesthetic .Other long acting local
anesthetics are  tetracaine  and  levo bupivacaine.
Amide type-Bupivacaine and Levo bupivacaine.
Onset time-5to 10 minutes.
Total duration of spinal block-90-120 minutes.
MECHANISM OF ACTION OF BUPIVACAINE
All local anesthetics block  sodium channels  and block entry of sodium into
the cells thereby preventing depolarization. So the nerve cannot get depolarized
and the signal is not propagated. In spinal anesthesia we commonly use hyperbaric
bupivacaine.
BARICITY OF THE SOLUTION; Baricity  determines the spread of local
anesthetic in the spinal space and is equal to the density of the local anesthetic
divided by the density of the CSF at 370  c.
The density of cerebrospinal fluid is less than 1.0069. In spinal anesthetics baricity
is mentioned in comparison to that of cerebrospinal fluid.
HYPOBARIC SOLUTION
When the solution of the drug has a density lesser than cerebrospinal fluid ,it
is called hypobaric bupivacaine. Hypobaric bupivacaine is produced when we boil
bupivacaine to 370c. These solutions tend to  spread upwards against gravity. It is
of use particularly  in fracture hip when the patient has to lie in a lateral position
with the operating site positioned above.
ISOBARIC SOLUTION
Isobaric solution of tetracaine is produced by adding nymphanoid crystals to
cerebrospinal fluid. Isobaric bupivacaine is also available. The height of the block
is dependent on the total milligram of the drug instilled in to the subarachnoid
space. Isobaric bupivacaine is available in the concentration of 0.5% and 0.75%.
HYPERBARIC SOLUTION
Hyperbaric bupivacaine is available in the concentration of 0.5% and 0.75%
in dextrose 8.25%. It is widely used. The height of block  is more dependant on the
position of the patient after the block.
SADDLE BLOCK
Make the patient sit. The local anesthetic gets concentrated in the sacral
area.
HEAD DOWN POSITION
More concentrated in the thoraco lumbar region.
LATERAL POSITION
 Dense block on the dependant side.
FACTORS DETERMINING THE CHARACTER OF BLOCK
? Potency of the spinal anesthetic  is related to the  lipid solubility.
? The  total duration of action of the anesthetic is more related to the
protein binding.
? The onset of action is related to the  availability of the drug in the base
form.
Lipid  solubility determines  the potency of the anesthetics. Low lipid
soluble medications need to be given in  higher concentrations of local anesthesia
to obtain the expected  nerve blockade. High lipid solubility can elicit   anesthesia
at low concentrations. Protein binding determines  the duration of action of the
anesthetic. Higher  proportions of  protein binding results in longer duration of
action.
pKa of a solution
The pKa of a local anesthetic is defined as  the pH at which ionized and
nonionized  forms  are  present  in   equal   concentrations  in  solution.  pKa  of
bupivacaine is 8.1.This is important because the nonionized easily  diffuses across
the lipophilic nerve sheath and acts on  the sodium channels in the nerve
membrane. The onset of action is more dependant on the amount of the medication
available in the base form. All local anesthetics obey  the rule that  “If  the pKa is
lower ,  the onset of action is faster”.
The fate of local anesthetics  in the Subarachnoid Space
Pharmacokinetics of local anesthetic consist of  uptake and elimination of
the drug. Four factors play a role in the uptake of local anesthetics from the
cerebrospinal fluid  into neuronal tissue.
The factors are
(1) concentration of the dug  in cerebrospinal fluid,
(2) surface area of neurons  present in  CSF,
(3) lipid content of neurons,
(4) vascularity of the nervous  tissue.
The uptake of local anesthetic is most dense  at the site of highest
concentration in the CSF and is decreased proportionately upwards and
downwards from this point.
Local anesthetics  in the subarachnoid space are taken up both by the  nerve
roots  and  the  spinal  cord.  If  the  surface  area  of  the  nerve  root  is  high   ,  the   the
uptake of local anesthetic  is greater.
There are  two postulated  mechanisms for the  uptake of local anesthetics in
the spinal cord.
The first method  is by simple  diffusion from the CSF to the pia mater and
thence into the spinal cord, which is comparatively a slow process. Only the
superficial layer of the spinal cord is affected by diffusion of local anesthetics.
The second method of  uptake of the drug  is by extension into the Virchow–
Robin spaces , which are the layers  of pia mater that surround the vasculature  that
penetrate the central nervous system. The spaces of Virchow–Robin are inter
connected with the neuronal clefts which surround nerve cell bodies in the spinal
cord and penetrate through to the deeper areas of the spinal cord.
The intensity of anesthetic effect depends on the
1.Diameter of the nerve fibers
2.Myelination of the nerve fibers.
3.conduction velocity
Order of affection of fibres in spinal anesthesia
1.Sympathetic neurons
2.Pain
3.Temperature
4.Touch
5.Proprioception
6.Tone of skeletal muscles
Spread  of local anesthetic in the subarachnoid space depends upon
  1. Attributed to the properties of the drug
? Baricity  of  the  drug
? Dose  given
? Volume  of  the  entire   solution
? Specific gravity of the solution
2.Patient characteristics
? Position of the patient  during and after injection
? Height of the patient which alters anatomy of the spinal column.
? Decrease in CSF volume which plays a major part when there is  increased
intra abdominal pressure due to increased weight, pregnancy, etc.
3.Technique
? Injection site  and the direction of the bevel of the needle.
FUNCTIONAL ANATOMY OF  SPINAL  BLOCKADE
Five ligaments hold the spinal column together.
They are;
1.supraspinous ligaments connect the apices of spinous processes
2.Inter spinous ligaments connect the spinous processes.
3.Ligamentum flavum connect the lamina above and below.
4.Anterior longitudinal ligament connect  the vertebral  bodies.
5.Posterior longitudinal ligament connect  the vertebral  bodies.
Important dermatomal levels
The tenth thoracic (T10) dermatome  -Umbilicus.
The sixth thoracic (T6) dermatome -Xiphoid.
The fourth thoracic (T4) dermatome- Nipples
Dermatomal levels needed for various surgeries
Procedure Dermatomal Level
For Upper abdominal surgery T4
Intestinal, gynecologic,  urologic
surgery
T6
Transurethral resection of the
prostate
T1O
Vaginal delivery of a fetus, and
hip surgery
T10
 Lower leg surgery L1
Foot and ankle surgery L2
Perineal and anal surgery S2 to S5 (saddle block)
Absolute contraindications to spinal anesthesia:
? When there is Patient refusal
?  Presence of Sepsis at the site
?  Severe Hypovolemia
? Coagulopathy
? Indeterminate neurologic disease
? Increased intracranial pressure
Relative contraindications
? Infection distant from the site of injection
?  Duration of surgery is not known.
PHYSIOLOGY OF SPINAL ANESTHESIA
Cardiovascular changes after spinal anesthesia
Spinal anesthesia causes  sympathectomy. So major hemodynamic changes
occur during spinal anesthesia. Sympathetic flow is thoraco lumbar flow. The
height of the block determines the extent of blockade of sympathetic system. So
hypotension and bradycardia, the important effects of sympathetic blockade are
common after spinal anesthesia.
Hypotension is caused due to both arteriolar  dilatation and veno dilatation.
Veno dilatation is more than arteriolar dilatation. Pre load to the  heart mainly
depends on the position of the patient after spinal anesthesia. Veins above the heart
cause increase in venous return whereas veins below the heart cause pooling of
blood.
Bradycardia occurs due to sympathetic blockade of cardio accelerator fibers.
Bradycardia is exaggerated in young people and in patients and in patients who are
on betablockers for a long time.
Risk factors for causing exaggerated hypotensive response after spinal
anesthesia
1.Volme contracted state(Hypovolemia)
2.History of  Hypertension
3.High Level of  sensory block
4. Age more than 40 years
5.Obesity,elevated BMI
6.Combination of  general and spinal anesthesia
7.Addition of  adjuvants like phenylephrine to the local anesthetic
8.History of  Chronic alcohol consumption
Decreased venous return can be treated by
? Crystalloid infusion
? Trendelenburg position
? Combined alpha and beta adrenergic agonist like ephedrine.
Excessive  crystalloid infusion can result in cardiac failure and pulmonary
edema. It may necessitate catheterization of bladder also.
Head down position should be restricted to 200 down. Inclination more than
this can decrease cerebral perfusion due to increased pressure in the internal
jugular vein.
The Bezold Jarisch reflex
This is a cardio inhibitory reflex. It may occur after central neuraxial
blockade.
Classical triad consists of
? Bradycardia
? Hypotension
? Cardio vascular collapse.
Bezold Jarisch reflex   is not a vaso vagal reflex.
Changes in respiratory system after spinal anesthesia
Pulmonary function is not altered much after spinal anesthesia. Lung
volumes, dead space, arterial blood gas, minute ventilation and shunt fraction  do
not change to a great extent after spinal anesthesia. The main effect seen is
paralysis of intercostal and abdominal muscles which result in decrease in peak
expiratory flow.
Patients  with  obstructive  pulmonary  disease   who  depend  on   accessory
muscles for effective  ventilation  can show a reduction in respiratory function
after spinal anesthesia.
Patients with normal respiratory function may experience dysnoea
sometimes. If they are able to vocalize properly ,there will not be any respiratory
compromise.
Minimal oxygen supplementation is a must in spinal anesthesia.
Changes in gastrointestinal system after spinal anesthesia
Gastro intestinal system receives sympathetic fibres from T6 toL2.
Due to  unopposed vagal activity ,the following changes occur
? Relaxation of sphincters
? 2.Increase in secretions.
? 3.contraction of bowel
These changes usually lead to nausea. So, atropine is more beneficial in combating
nausea after spinal anesthesia.
Changes in hepatobiliary system after spinal anesthesia
Hepatic blood flow  is predominantly related to arterial blood flow.  Spinal
anesthesia decreases venous return. Pre load is decreased. Hence arterial pressure
and cardiac output get reduced. As arterial blood supply is decreased, total blood
flow to the liver decreases after spinal anesthesia. Hepatic blood flow
predominantly depends on the mean arterial pressure. If  mean arterial pressure
(MAP) is maintained , hepatic blood flow is  maintained.
Patients with liver  diseases should be carefully monitored and mean arterial
pressure should be maintained with in normal limits. In patients with liver disease
either regional or general anesthesia can be given, as long as the MAP is kept close
to baseline.
AUTOREGULATION OF RENAL BLOOD FLOW
Autoregulation of blood flow to the kidney is well maintained above a mean
arterial pressure of 50 mm Hg.Renal blood flow is decreased when the mean
arterial pressure becomes lower than 50 mm Hg.
EQUIPMENTS FOR SPINAL ANETHESIA;
1.Spinal tray
a.sponge holding forceps
b.sterile gauzes
 c.bowl
d.sterile drapes
2.Spinal Needle
Spinal needle consists of a needle and a close fitting removable stylet.
        Different types available are;
             a. Quinke’s needle
            b. Sprotte’s needle      Pencil point needles
           c. Whitaker’s needle
     Needles are available in gauges of 29,27,25,23.
POSITION OF THE PATIENT
Proper positioning is essential for technical ease and a resultant successful
block. A trained technician should be present to  keep the patient in optimal
position.
The different positions are
       1.Lateral decubitus position.
        2.Sitting position.
       3.Prone position in rectal, perineal and lumbar surgeries if the patient needs to
be in that position  during surgery.
Patient In Sitting Posture
Technique of lumbar puncture
Appropriate monitors must be connected.
Airway and resuscitation equipments  are kept  available.
Oxygen supplementation for all patients.
Skin is cleaned with sterile cleaning solution
The area is  draped  with a sterile central hole towel.
A small wheal of local anesthetic,2% lignocaine  is injected  at the site of
insertion.
The various approaches are;
1. Midline approach.
2. Paramedian approach
3. Taylor’s approach.
MIDLINE APPROACH
1. Iliac crests are palpated .The line between the two iliac crests  intersects
L4 vertebra or L4-L5 space.
2. Palpate the interspace  and the spinal needle is inserted.
3. The spinal needle passes through the following structures;
 a.Skin
 b.Subcutaneous  tissue
 c.Supraspinous ligament
 d.Inter spinous ligament.
 e.Ligamentum flavum.
 f.Epidural space.
 g.Duramater
           h.Arachnoid mater
2.Paramedian or lateral approach
Two methods are available
First method is
? The needle is inserted 1 cm lateral to the spinous process.
? First structure to be felt is usually ligamentum flavum.
? Then the needle is directed towards the midline.
Second method is
? The needle is inserted 1 cm lateral and inferior to the interspace.
? Lamina is encountered.
? Walk through the lamina and enter the sub arachnoid space
PARAMEDIAN APPROACH OF LUMBAR PUNCTURE
3.TAYLOR APPROACH
A paramedian approach    in which the needle is directed toward the L5-S1
interspace.
L5-S1 interspace is the largest space  and can be tried if other methods fail.
It can be done in any position namely lateral decubitus, sitting or prone.
The needle is  inserted at a point 1 cm medial and inferior to the posterior
superior iliac spine, then angled cephalad 45–55 degrees.
The needle is directed medially  to reach the midline at the L5 spinous
process. The first significant resistance  is the ligamentum flavum, and then the
dura mater is punctured.
.Complications of spinal anesthesia
A.Local anesthetic induced neurotoxicity and neurological injury.
B.Cardio vascular instability.
C.High blockade.
D.Post dural puncture headache.
E.Transient neurological symptoms more common with lidocaine.
F.Permanent neurological injury.
1. Cauda equina  syndrome.
2. Arachnoiditis.
3. Meningitis
4. Spinal hematoma formation.
Factors to be followed to reduce neurological complications
? Absolute sterility.
? Assurance of normal coagulation parmeters.
? Lowest efficient dose of the drug.
? Complete neurological examination  before spinal anesthesia.
? Use of preservative free solution.
MATERIALS AND METHODS
AIM OF THE STUDY
The purpose of this study was to investigate the effect of small single dose
intravenous dexmedetomidine administration on prolonging  duration of
hyperbaric bupivacaine spinal anesthesia. Institutional ethical board committee
approval was obtained before the commencement of the study.
Sample size calculation
This study was a prospective randomized controlled study. Study population
comprised of 100  adult patients classified as ASA 1 or 2  who were  scheduled for
total abdominal hysterectomy or  vaginal hysterectomy  under spinal anaesthesia.
INCLUSION CRITERIA
1) ASA grade I-II
2) Age < 60 years
3)Patients who were posted for  Total abdominal Hysterectomy and vaginal
hysterectomy under spinal anesthesia.
EXCLUSION CRITERIA
1) Patients on sedatives/opioids/antidepressants in the week prior to
surgery.
2) Patients with morbid obesity.
3) Patients with diabetes and renal disease.
4) Pre-operative baseline heart rate equal to or less than 60/min
5) Pre-operative baseline systolic blood pressure equal to or less than  90
mm Hg.
All patients were  examined on the day prior to surgery  and pre anesthetic
evaluation chart was checked. Special consideration was given to elicit
hypertension, breathlessness, pain, cough, wheezing ,previous anesthesia and drug
sensitivity. The patient’s weight, height was measured. The  nutritional status,
airway assessment, spine examination were also done on the previous day.
 A  detailed  examination  of  all  systems  was  done.  Pre  operative   routine
investigations such as hematocrit ,renal function tests, complete blood count, blood
grouping, platelet count, chest radiography, electrocardiography were checked
properly.
All patients were informed about the procedure and written consent was
taken. All patients were kept nil per oral for 10 hours  and were given
premedication with tablet alprazolam 0.5 milligram, tablet. ranitidine 150
milligrams and tablet metaclopramide 10 milligram  on the  night before surgery.
After putting the patient on operating  table   electrocardiography, peripheral
saturation of oxygen (SpO2) and non-invasive blood pressure monitor and all the
basal parameters were recorded. An IV access with  18 gauge cannula and all
patients were preloaded with Ringer lactate solution 10 ml/kg body weight.
Patients  were   randomly  allocated  to  one  of  the  two  groups  by  slips  in  box
technique.
Patient was put in lateral decubitus position.Lumbar puncture was
performed  at L3-L4 level with Quincke type 25 gauge spinal needle and injection
hyperbaric bupivacaine 17.5 mg  was given intrathecally over 30 seconds. If there
was technical difficulty at L3- L4 level ,one more try was given at L2-L3  level
with Quinckes needle25 gauge. If found un successful those patients were
excluded from the study.
In group D patients  received  hyperbaric intrathecal bupivacaine anesthesia
3.5ml 0.5% (17.5 mg) and intravenous Dexmedetomidine 0.5mcg/Kg in10 ml
normal saline over 10 minutes.
In group C patients  received  Hyperbaric bupivacaine anaesthesia 3.5 ml
0.5% (17.5mg) and intravenous normal saline 10 ml over 10 minutes.
Vitals were recorded  [Heart rate, Non invasive blood pressure monitoring,
pulseoximetry, Respiratory rate] every 5 min till the end of surgery and then every
5 min in post anaesthesia care unit.
MONITORING OF PATIENTS
Hypotension  was   defined  as systolic BP of less than 90 mm Hg or 25%
lesser than the baseline value  and was treated  with  6 mg of  Inj. Mephenteramine
intravenously.
Bradycardia  was defined as  heart rate <50/min  and  was  treated  Inj.
Atropine 0.6 mg.
ASSESSEMENT OF SENSORY BLOCKADE
Sensory blockade was checked with an alcohol swab in mid axillary line .
Sensory blockade was  assessed after 5 minutes and there after maximum level of
blockade was  noted . After this point surgery was started. Vitals monitored
through out the procedure. At the end of surgery, sensory level was noted. Two
dermatome regression time from the maximal level and regression to level S1was
noted every 20 min  post operatively. Time of spinal injection was taken as 0.
ASSESSMENT OF MOTOR LEVEL
      Motor level  was assessed using Modified  Bromage scale[38] at 5th minute and
every 20 min  after the end of surgery.
1. BROMAGE0-Able to move hip, knee, ankle.
2. BROMAGE1-Unable to move hip ,but is able to move knee and ankle.
3. BROMAGE2-Unable to move hip and knee but is able to move  the ankle.
4. BROMAGE3-Unable to move hip, Knee and ankle.
ASSESSMENT OF SEDATION
Sedation was assessed by Ramsay sedation scale[39] at the 5th minute. Again
sedation was assessed at the end of the surgery. Level of sedation was evaluated
every 20 minutes post operatively for 4 hours.
Ramsay Level of sedation scale.
1. Awake and anxious, agitated, or restless
2. Awake, cooperative, accepting ventilation, oriented, tranquil
3. Awake; responds only to commands
4. Asleep; brisk response to light glabellar tap or loud noise
5. Asleep; sluggish response to light glabellar tap or loud noise
stimulus but does not respond to painful stimulus
6. Asleep; no response to light glabellar tap or loud noise
Patient Posted For Abdominal/Vaginal Hysterctomy Under
Spinal Anesthesia  Selected According To Inclusion Criteria
Informed Consent Obtained
Patient Shifted  Inside Operation Theatre
WHO Check List Carried Out
Group Alloted By Slips Of Paper In A Box Technique
Pulsoximetry,ECG Leads, NIBP Connected And Vitals
Checked And Recorded
Preloaded With Ringers Lactatate 10ml/Kg
Spinal  Block  Performed In The  Lateral Decubitus
Position
Patient  was  placed   in  lateral  decubitus  position,  Quinkes 25 gauge
needle was inserted . Sub arachnoid block performed  by giving
0.5% hyperbaric bupivacaine 3.5 ml(17.5 mg) given over 30 seconds.
After   Spinal   Anesthesia Patient Was Put Back To
Supine Position
Group C
( control group
Selected randomly)
Received
Iv normal saline given over 10 minutes
At the 5 th minute sensory block level checked with alcohol swab,motor
block level according to Modified Bromage scale,sedation score as per
Ramsay sedation score and noted in the master chart.
Surgery     started  vitals monitored continously
If heart rate fell below 50 inj. Atropine0.6 mg was given. If blood
pressure fell below 90/60 inj Mephenteramine 6 Mg Was given.
group    D
(dexmedetomidine group
selected
randomly)
received  intravenous
dexmedetomidine
o.5 microgram per kg
given  in 10  min
At The End Of Surgery Sensory Level, Grade Of Motor
Block , Sedation Score Noted
After this sensory level, grade of motor block , sedation score
checked every 20 minutes for 260 minutes. Continous
monitoring of vitals carried on till 260th minute.
RESULTS AND ANALYSIS
100 patients  were enrolled in the study ,50 patients were randomly allocated
into  the study group and 50 patients to  the  Control  group. All 100 patients
successfully completed the protocol and they were included in the analysis of data.
The demographic data of the patients in the two groups were studied and the
analysis revealed no significant difference in both the  groups. In the demographic
data the continuous variables studied were age, body mass index.
DEMOGRAPHIC DATA
groupcode Number Mean Std. Deviation Std. Error Mean
study group 50 48.24 4.792 0.678
control group 50 48.78 4.82 0.682
study group 50 53.64 2.905 0.411
control group 50 53.2 2.399 0.339
study group 50 151.54 3.215 0.455
control group 50 151.38 3.09 0.437
study group 50 23.39 1.67 0.24
control group 50 23.24 1.41 0.20
character
Group Statistics
Age
wt
Height
BMI
GRAPHIC REPRESENTATION OF DEMOGRAPHIC VARIABLES IN
BOTH THE GROUPS
From this graph  as the line joining the means of both groups is a straight
line  it is clearly  evident that  both the groups  were similar in all the
characteristics like age, height, weight, BMI.  As the study was conducted  in
abdominal hysterectomy and vaginal hysterectomy only, the type of surgery  and
the sex of the patients were  not taken for  comparison.
DESCRIPTIVE ANALYSIS OF DEMOGRAPHIC  VARIABLES
Demographic variables like age, weight, height and BMI  were compared
using Levene’s test  for equality of variances  and independent sample T test  The
p value was found  not to be significant.
Independent Samples Test
Levene's Test for Equality of Variances t-test for Equality of Means
95% Confidence Interval of the Difference
F P  value t df Sig. (2-tailed) Mean Difference Std. Error Difference Lower Upper
Age
Equal variances
assumed
0.001 0.977 (NS) -0.562 98 0.576(NS) -0.54 0.961 -2.448 1.368
wt
Equal variances
assumed
0.809 0.371 0.826 98 0.411(NS) 0.44 0.533 -0.617 1.497
Height
Equal variances
assumed
0.258 0.612 0.254 98 0.8(NS) 0.16 0.631 -1.091 1.411
BMI
Equal variances
assumed
0.294 0.589 0.482 98 0.631(NS) 0.1487867 0.308793 -0.4640029 0.7615764
character
COMPARISON OF HEART RATE IN THE TWO GROUPS
THROUGHOUT THE STUDY PERIOD
Heart Rate STUDY CONTROL
PRE OP 86.44 84
MEAN HR at 5 min 74.14 75.9
MEAN HR at 20 mi 58.64 107
MEAN HR 40min 59.78 72.7
MEAN HR60 min 59.32 70.3
MEAN HR 80min 59.4 75.3
MEAN HR100min 60.6 69.8
MEAN HR120min 57.42 70.68
MEAN HR140min 63.22 77.06
MEAN HR 160min 62.86 74.36
MEAN HR 180min 66.2 70.87
MEAN HR 200min 63.54 77.01
MEAN HR 220min 70.56 82.01
MEAN HR 240min 73.8 85.19
MEAN HR 260min 72.9 78.2
GRAPHIC REPRESENTATION OF MEAN HEART RATE THROUGH
OUT THE STUDY PERIOD
It is clearly evident that the mean heart rate pre operatively and 5 minutes
after  spinal  anesthesia  was  almost  similar  inboth  the  groups.  But  after  this  both
intra operatively and post operatively patients in the study group had significantly
lower heart rate than in the control group.
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COMPARISON OF MEAN ARTERIAL PRESSURE IN BOTH THE
GROUPS THROUGH OUT THE STUDY PERIOD
Mean arterial pressure Study
group
Control group
MEAN MAPat 5 min 90.29 76.6
MEANMAP at 20 min 82.92 84.4
MEAN MAPat 40 min 72.46 86.4
MEANMAPat 60 min 72.74 94.2
MEANMAP at 80 min 72.7 90.6
MEANMAPat 100 min 73.03 82.87
MEANMAPat 120 min 72.9 83.82
MEANMAPat 140 min 73.07 82.14
MEANMAPat 160 min 73.14 85.45
MEANMAPat 180 min 73.24 80.26
MEANMAPat 200 min 72.86 80.19
MEANMAPat 220 min 72.95 84.31
MEANMAP at 240 min 73.07 84.4
MEANMAPat 260 min 73.24 83.03
GRAPHIC REPRESENTATION OF
MEAN ARTERIAL PRESSURE THROUGH OUT
THE STUDY PERIOD
This graph clearly depicts that the mean arterial pressure was comparatively
low in the study group which received dexmedetomidine than in the control group.
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COMPARITIVE STATISTICAL ANALYSIS OF MEAN ARTERIAL
PRESSURE AND MEAN HEART RATE IN THE TWO GROUPS
Levene's Test
for Equality of
Variances
t-test for
Equality of
Means
F P  value t df Sig. (2-tailed)
Mean
Difference
MEANMAP
Equal
variances
assumed
3.01 0.086 -32.98 98 0.0001*** -17.9047619
MEANHR
Equal
variances
not
assumed
11.41 0.001 -15.79 98 0.0001*** -13.3528571
Levene's Test
for Equality of
Variances
t-test for
Equality of
Means
F P  value t df Sig. (2-tailed)
Mean
Difference
MEANMAP
Equal
variances
assumed
19.8 -0.084 1.387 98 0.0001*** -8.8009523
MEANHR
Equal
variances
not
assumed
28.2 -0.169 18.57 98 0.0001*** -4.2490475
Both groups were compared in terms of mean arterial pressure and mean
heart rate by independent sample test and Levene’s test for equality of variances
and the  p value was found to be highly significant.
COMPARISON OF PATIENTS WHO RECEIVED ATROPINE IN BOTH
THE  GROUPS
In the dexmedetomidine a total of 10 patients  recived atropine while  only 2
patients in the control group received atropine.
PARAMETER
DEXMEDETOMIDINE
GROUP CONTROL GROUP
NO OF PATIENTS WHO
RECEIVED ATROPINE 10 2
ASSESSMENT OF  MOTOR LEVEL AT 5  MINUTES
Percentage Study group Control  group
Number of
patients
Percentage Number
of
patients
Bromage 3 50 100% 50 100%
At the 5th minute ,before the onset of surgery motor level was checked. All
the patients in both the groups were not able to move the hip and showed Bromage
grade 3.  It is clear from this graph that there was no  change in achieving the
maximal level  in both the groups. Although the onset of motor block was not
compared in our study ,we could not make out any significant difference in both
the groups in the onset of sensory and motor blockade.
ASSESSMENT OF SENSORY LEVEL AT 5 MINUTES
It is evident from the graph that both in the study and control groups the
maximal level of block was the same.
MOTOR BLOCK AT 160 MIN
 Motor
block
Dexmedetomidine
group
Control             group
At 160
minutes
Number
of
patients
Percentage Number
of
patients
Percentage
B1 0 0% 8 16%
B2 7 14% 37 74%
B3 43 86% 5 10%
After 160 minutes of spinal anesthesia ,in the study group 43 out of 50
patients were not able to move the hip, knee and ankle .But in the control group,37
out of 50 patients were able to move only the ankle while 8 out of 50 were able to
move knee and ankle. Only 5 patients (10%) had Bromage 3 while 43 patients
(86%) in the study group had Bromage 3.
ASSESSMENT OF MOTOR BLOCK AFTER 160 MINUTES
Motor block was assessed using modified Bromage scale . This bar diagram
clearly depicts the significant difference in the motor block in both the  groups.
ASSESSMENT OF SENSORY BLOCKADE AT 160 MIN
SENSORY BLOCK AT 160 MINUTE
Sensory block assessed at 160 minutes showed a level of T6 in 48% andT8
in 52% of the patients in the study group . In the control group  it was T10 IN 34%
and T12 in 56% of the patient .Only 10% of thr patients in the control group
showed a level of T8.
sensory level at 160 min
NUMBER PERCENTAGE NUMBER PERCENTAGE
T10 0 0% 17 34%
T12 0 0% 28 56%
T6 24 48% 0 0%
T8 26 52% 5 10%
STUDY GROUP CONTROL GROUP
COMPARISON OF DURATION OF MOTOR BLOCK IN TWO GROUPS
The  time  for  the  motor  block  to  become  B0  was 243±17.0 minutes in
the study group  and  in  the  control  group  it  was  211.2±16.7 minutes. This
showed a significant prolongation of motor block in the dexmedetomidine group
with a p value of 0.001***.
Group Statistics
groups NUMBER Mean
Std.
Deviation
Std. Error
Mean
DEXMEDETOMIDINE
GROUP
50 243.6 17.0 2.4
CONTROL GROUP 50 211.2 16.7 2.4
TIME FOR MOTOR
BLOCK TO BECOME
BROMAGE    O
PARAMETER
Levene's Test for Equality of Variances t-test for Equality of Means
Equal variances
assumed
F test
value
p value
t test
value
p value
Mean
Difference
Std. Error
Difference
Lower Upper
TIME FOR MOTOR
BLOCK TO BECOME
BROMAGE    O
0.223 0.638 9.605 0.001*** 32.4 3.373 25.706 39.094
Independent Samples Test
95% CI of the
COMPARISON OF DURATION OF SENSORY BLOCK IN TWO GROUPS
PARAMETER Group Statistics
groups NUMBER Mean Std.
Deviation
Std.
Error
Mean
TIME FOR
SENSORY
LEVEL TO
BECOME  S1
DEXMEDETOMIDINE
GROUP
50 255.2 8.6 1.2
CONTROL GROUP 50 210.8 33.1 4.7
The total time for sensory level to reach S1 was 255±8.6in the study group
while it was  210.8±33,1 in the control group. This also proved significant
prolongation in the study group with a p value of 0.001***.
Levene's Test for Equality of Variances t-test for Equality of Means
Equal variances
assumed
F test
value
p value
t test
value
p value
Mean
Difference
Std. Error
Difference
Lower Upper
TIME FOR SENSORY
LEVEL TO REACH S1
7.281 0.008 9.172 0.001*** 44.4 4.841 34.793 54.007
95% CI of the
Independent Samples Test
COMPARISON OF TIME OF TWO DERMATOME REGRESSION  IN
TWO GROUPS
The time for two dermatome regression from the maximal level was
125.2±17.5minutes  in the study group and 94.6±18.9 in the control group. This
proved the significant prolongation of sensory block to regress from the maximal
level in the study group with a p value of   0.001 ***.
Group Statistics
groups NUMBER Mean
Std.
Deviation
Std. Error
Mean
DEXMEDETOMIDINE
GROUP
50 125.2 17.5 2.5
CONTROL GROUP 50 94.6 18.9 2.7
TIME FOR
REGRESSION FROM
MAXIMAL LEVEL
PARAMETER
Levene's Test for Equality of Variances t-test for Equality of Means
Equal variances assumed
F test
value
p value
t test
value
p value
Mean
Difference
Std. Error
Difference
Lower Upper
TIME FOR THE
REGRESSION OF
SENSORY LEVEL
FROM MAXIMUM
1.062 0.305 8.403 0.001*** 30.6 3.642 23.373 37.827
Independent Samples Test
95% CI of the
                       SEDATION LEVEL AT 140  MINUTES
At 140 minutes the patients who received dexmedetomidine remained
calm and sedated  with Ramsay sedation grade of 3 or 2.
STUDY GROUP C ONTROL GROUP
Sedation
140 min
Numberof
patients
Percentage Number of
patients
Percentage
R1 0 0.00% 45 90.00%
R2 12 24.00% 5 10.00%
R3 38 76.00% 0 0.00%
SEDATION SCALE AT 140 MINUTES
DISCUSSION
There has always been immense research to improve the effects of spinal
anesthesia by changing drug regimens and technical methods. Usually adjuvants
are added to hyperbaric bupivacaine and instilled intrathecally to prolong the
anesthetic effects.  These adjuvants act  perineurally or at different sites in the
spinal  cord  and  exert  their  antinociceptive  action.  They   prolong  anesthesia  and
decrease pain in the post operative period.
In the past clonidine, alpha 2 agonist has been used in oral, intrathecal,
intravenous  routes to prolong spinal anesthesia. The previous studies have proved
that clonidine 30 micrograms is equivalent to dexmedetomidine 3 micrograms
intrathecally. The  proven  advantages of dexmedetomidine are minimal
depression of respiration  cardioprotection,  renoprotection and neuroprotection.
This prospective randomized controlled study  conducted in 100 patients
who underwent abdominal/vaginal hysterectomy under spinal anesthesia
demonstrated that dexmedetomidine given in the dose of 0.5 microgram/kg
prolonged the sensory and motor block significantly.
Both the groups were comparable in demographic parameters like age,
weight, height and BMI. The mean age of all the patients in the dexmedetomidine
group was 48.24±4.7.The mean age of the patients in the control group was
48.78±4.82. The mean body mass index  for all the patients in dexmedetomidine
group was 23.39±1.67.The mean body mass index for all the patients in the control
group was 23.24±1.41. They were compared using independent sample test and
Levene’s test for equality of variances  and  the p value was found  not significant.
At the 80th  minute  the average mean arterial pressure in the
dexmedetomidine group was around 72 whereas in the control group it was around
90   .   The  mean  heart  rate  of  all  the  patients     after     40   minutes  of  spinal
anesthesia    was 72 in the control group  whereas in the dexmedetomidine  group
it was 58.Statistical analysis was done for mean arterial pressure and mean heart
rate and the p value was found to be highly significant.     This has proved the fact
that dexmedetomidine has got a  definite  role  in  hypotensive  anesthesia.
In our study the number of patients who received   atropine was more than
in the control group  because of  bradycardia caused by dexmedetomidine  induced
sympatholysis. In the dexmedetomidine group 10 out of 50 patients needed
atropine whereas in the control group only 2 patients needed atropine. This
bradycardia promptly responded to Inj. Atropine 0.6mg intravenously. During our
study there was no other adverse effect of dexmedetomidine  observed in the study
group. This may be due to the fact that we had used only moderate  dose of
dexmedetomidine  as a  single intravenous injection given slowly over 10 minutes.
At  the  fifth  minute   of  spinal  anesthesia  ,grade  of  motor  level  and  sensory
level was checked. All the patients in both the groups were not able to move the
hip and showed Bromage 3. All the patients in both the groups had a sensory level
of T4.This showed that there was no difference in achieving  the  maximum  motor
and  sensory  level in both the groups.
At the 160th minute of spinal anesthesia grade of motor level was Bromage 3
in 43 patients in the dexmedetomidine group(86%). But in the control group  only
5 patients(10%) had  Bromage grade 3.This demonstrated that there was a
prolongation of motor block in the dexmedetomidine group.
At the 160th minute of spinal anesthesia,24 patients(48%) had a sensory
level of T6 in the dexmedetomidine group. But in the control group no patient had
a sensory level of T6.In the control group,17 patients (34%) had a sensory level of
T10. This was the maximum level seen at 160th minute in the control group.
The   time   for   the   motor   block   to   become   Bromage  grade  0   was
243±17.0 minutes in the dexmedetomidine  group  and  in  the  control  group  it
was  211.2±16.7 minutes. This  on statistical analysis by independent sample test
and t test for equality of means showed a significant prolongation of motor block
in the dexmedetomidine group with a p value of 0.001***.
Al Mustafa et al.     in their study in 48  patients  had demonstrated similar
prolongation 199 ± 42.8 min vs. 138.4 ± 31.3 min (P < 0.05). They had given
isobaric bupivacaine 12.5 mg for spinal block In our study  the  total duration  of
motor block was more  in  both the control and study groups when compared to Al
mustafa et al . This may be due to the fact that we had given hyperbaric
bupivacaine 17.5 mg.
 Dinesh  et  al  had  done   a  similar  study  in  100  patients  with   15  mg  of
hyperbaric bupivacaine   and they had given dexmedetomidine 1 microgram/kg as
a loading dose and 0.5 microgram/kg/hour as maintenance dose. They
demonstrated the regression time to reach the modified Bromage scale 0 was
significantly prolonged in the dexmedetomidine group (220.7 ± 16.5 min)
compared to the control group (131.6 ± 10.5 min).
 In our study, the total time for sensory level to reach S1 was 255±17.5in the
study   group  while  it  was   210.8±33.1  in  the  control  group.  Dinesh  et  al  had
demonstrated that the total  duration of sensory blockade was significantly
prolonged in the dexmedetomidine group (269.8 ± 20.7 min) whereas it was 169
minutes   in   the  control  group  (169.2  ±  12.1)  .  We had  got  the  almost  similar  to
the results  seen  in  other studies. Al Mustafa et al., whose study formed the basis
of our dissertation  had 261.5 ± 34.8 min in the study group  vs. 165.2 ± 31.5 min
in the control group  (P < 0.05. Dexmedetomidine group had higher level of
sensory block compared to the control group in our study, similar to the study
results of Kaya et al.
In our study the time for two dermatome regression from the maximal level
was 125.2±17.5minutes  in the study group and 94.6±18.9 in the control group.
This proved the significant prolongation of sensory block to regress from the
maximal level in the dexmedetomidine group with a p value of 0.001***. This
showed  the prolongation of sensory block by intravenous dexmedetomidine.
Dinesh et al  had  given 15 mg of hyperbaric bupivacaine . They had given
dexmedetomidine 1 microgram/kg as a loading dose and 0.5 microgram/kg/hour as
maintenance dose.  They demonstrated that   the mean time for two-dermatomal
regression of sensory block was significantly prolonged in the group that received
dexmedetomidine (137.4 ± 10.9 min) compared to the other  group (102.8 ± 14.8).
Sudhesh,K.Harsoor  in the article dexmedetomidine  a wonder drug  has
clearly mentioned about the transient hypertensive response when
dexmedetomidine is given in the dose of 1-4 microgram/kg. Jia Song et al in the
article titled  dexmedetomidine for sedation in patients undergoing surgery under
regional anesthesia  has clearly mentioned that as the dose increased the incidence
of hypotension also increased. In their study they had given a loading dose of 1
microgram/kg and  they had advised that maintenance dose 0.25
microgram/kg/hour may be most appropriate  if severe bradycardia  and
hypotension have to be avoided. Dexmedetomidine is given intravenously in doses
ranging from  0.1 to 1 ?g/kg/h but higher doses is usually associated with a
significant incidence of bradycardia and hypotension. Aantaa et al., had concluded
that “The optimal dose of dexmedetomidine for single dose intravenous
premedication in minor surgery has wide safety margins in the  range of 0.33 to
0.67 ?g/kg”. Hence   we selected a dose of 0.5 ?g/kg in our study. While  deciding
on the dose of single intravenous dose of dexmedetomidine these articles were
given utmost importance.
We decided on the dose 0.5microgram/kg to be given slowly over 10
minutes so as to avoid  side effects and to get the desirable therapeutic  effect.
When given intravenously the half life of dexmedetomidine is 2-3 hours. All the
patients were closely monitored for 5 hours. This is a great advantage  of
dexmedetomidine  over clonidine whose half life is 6-10 hours.
 In our study  no patient had transient hypertension . The transient
hypertensive response due to peripheral alpha2 receptor stimulation occurs when
dexmedetomidine is given in the dose more than 1 microgram/kg.
Post operatively when the sensory level touched T12-L1  most of our
patients complained of pain with some discomfort. Rescue analgesic Inj.
Paracetamol 1gram intravenously was administered to those patients who
complained.
It is a common practice to  sedate patients with midazolam who are under
spinal anesthesia. Kaya etal  in their article had compared midazolam and
dexmedetomidine and had clearly explained about the superiority of
dexmedetomidine over midazolam.
Intraoperatively the patients in the study group showed significantly high
sedation scores than in the control group. In their study’ Kaya et al had reported
about the paradoxical reactions of midazolam   when given in high doses.
Dexmedetomidine is unique in causing arousable sedation. All patients who
received dexmedetomidine  had  good sedation score  through out the intra
operative period   ( Ramsay sedation score R3-R2)compared to the control group .
At 140 th minute 76% of the patients in dexmedetomidine group remained sedated
with the grading of Ramsay 3.
We had assessed sedation level at the 5th minute  and  then  at  the  end  of
surgery. The average duration of the surgery was around 130 minutes. The peak
action of dexmedetomidine  is  around  10-20 minutes. We could see the patients
sleeping well when the surgery was going on. Some patients  snored  but there was
no incidence of  desaturation.
All patients  in the study and control  group  were given  oxygen at the rate
of 2 liters/minute through ventimask. This clearly demonstrated the nature of
dexmedetomidine in causing  arousable sedation without respiratory depression.
As dexmedetomidine do not affect synthesis ,storage or metabolism of
catecholamines its actions can be easily reversed by vasopressors  or
anticholinergics. The availability of antagonist Atipamezole with similar
distribution and elimination characteristics is a great advantage for
dexmedetomidine over other anesthetic agents. Atipamezole is of particular use in
reversing the sedative effects of dexmedetomidine. In our study bradycardia
caused by dexmedetomidine  promptly responded to anticholinergics.
CONCLUSION
Dexmedetomidine  in the dose of  0.5 microgram/kg  given as single
intravenous dose to patients  who underwent abdominal/vaginal hysterectomy
under spinal anesthesia significantly prolonged the duration of sensory and motor
blockade. There was also significant prolongation of the time for the two segment
dermatome regression in the dexmedetomidine group compared to the control
group. All these effects were achieved without causing deep level of sedation and
with minimal hemodynamic side effects.
SL.No. NAME IP NO PRE OP DRUG
AGE WEIGHTHEIGHTBMI ASA BP HR AFTER 5 MINDIA SYS HR DRUG MOTORSENSORYSEDATIONSYS DIA BP HR DRUG MOTORSENSORYSEDATIONBP HR DRUG MOTORSENSORYSEDATIONBP HR
68 BANUMATHY 43 57 154 24.0344 1 22163896 145/90 102 NS 82 124 73 B3 T4 R1 100 70 100/70 89 123/84 73 112/76 71
69 NEELA 44 56 154 23.6128 1 12410869 134/86 99 NS 70 119 68 B3 T4 R1 109 78 126/76 80 120/76 78 112/56 67
70 SUGANTHI 55 55 150 24.4444 1 14411811 144/74 98 DEX 0.5 mcg/Kg78 132 67 B3 T4 R4 98 68 100/67 60 98/72 60 M6 111/77 50
71 MUNIYAMMAL43 50 149 22.5215 1 2288096 110/80 87 DEX 0.5 mcg/Kg80 140 92 B3 T4 R4 99 67 128/88 68 100/78 56 90/56 58
72 PAPPATHY 56 54 154 22.7694 1 16972056 144/74 86 NS 65 98 78 M6 B3 T4 R1 90 78 90/78 70 M6 100/68 67 100/76 70
73 JAYAMALADEVI46 50 150 22.2222 1 43808024 158/84 69 NS 76 109 87 B3 T4 R1 92 68 98/78 67 110/67 76 98/87 78
74 SASIKALA 47 56 143 27.3852 2 20743083 150/100 78 DEX 0.5 mcg/Kg57 108 60 M6 B3 T4 R3 100 89 100/89 56 A0.6 100/80 50 A0.6 100/78 56
75 RAMANI 40 50 154 21.0828 1 15619413 136/84 87 NS 78 110 78 B3 T4 R1 109 78 109/78 69 98/68 76 M6 100/70 78
76 JAYALAKSHMI 42 55 152 23.8054 1 21413547 146/80 87 DEX 0.5 mcg/Kg67 129 70 B3 T4 R4 100 78 100/78 50 A0.6 98/78 54 A0.6 90/50 62
77 GOMATHI 44 50 148 22.8269 1 15931401 130/92 78 DEX 0.5 mcg/Kg65 109 58 B3 T4 R4 122 90 98/78 58 90/78 67 M6 98/78 58
78 ARPUDAM 47 53 149 23.8728 2 16541215 160/80 79 NS 67 110 65 B3 T4 R1 123 89 100/87 78 110/89 77 112/78 66
79 CHINNAPONNU46 54 149 24.3232 1 124/88 76 NS 78 98 65 M6 B3 T4 R1 124 87 100/70 56 100/78 62 110/78 61
80 LILLY 45 55 150 24.4444 1 136/78 77 NS 90 140 87 B3 T4 R3 100 60 116/76 60 106/68 66 99/86 78
81 KAVITHA 46 56 151 24.5603 1 17746051 132/68 79 DEX 0.5 mcg/Kg80 140 92 B3 T4 R4 99 67 128/88 68 100/78 56 90/56 58
82 KUMARI 46 49 148 22.3703 2 21716914 134/69 78 NS 65 98 78 M6 B3 T4 R1 90 78 90/78 70 M6 100/68 67 100/76 70
83 KASTHURI 50 56 150 24.8889 1 21155291 120/80 76 NS 76 109 87 B3 T4 R1 92 68 98/78 67 110/67 76 98/87 78
84 CHANDRA 51 52 152 22.5069 1 11818766 134/67 75 DEX 0.5 mcg/Kg57 108 60 M6 B3 T4 R3 100 89 100/89 56 A0.6 100/80 50 A0.6 100/78 56
85 RAJALAKSHMI 52 53 154 22.3478 1 13871711 122/78 74 NS 78 110 78 B3 T4 R1 109 78 109/78 69 98/68 76 M6 100/70 78
86 AMUL 54 53 155 22.0604 1 16830219 120/78 65 DEX 0.5 mcg/Kg67 129 70 B3 T4 R4 100 78 100/78 50 A0.6 98/78 54 A0.6 90/50 62
87 VIJAYAKSHMI 55 54 156 22.1893 1 20030759 144/89 66 DEX 0.5 mcg/Kg65 109 58 B3 T4 R4 122 90 98/78 58 90/78 67 M6 98/78 58
88 SHANTHI 56 57 153 24.3496 1 21488650 140/80 68 NS 67 110 65 B3 T4 R1 123 89 100/87 78 110/89 77 112/78 66
89 JOTHI 54 56 154 23.6128 1 20513236 136/84 90 NS 78 98 65 M6 B3 T4 R1 124 87 100/70 56 100/78 62 110/78 61
90 GIRIJA 51 55 150 24.4444 1 20816437 136/84 89 NS 90 140 87 B3 T4 R3 100 60 116/76 60 106/68 66 99/86 78
91 CHANDRA 46 56 151 24.5603 1 21925194 146/80 88 NS 78 98 65 M6 B3 T4 R1 123 89 100/70 89 100/78 76 110/78 61
92 MAYA 46 49 148 22.3703 2 14004768 130/92 102 NS 78 122 87 B3 T4 R1 124 87 119/89 98 119/87 77 100/67 76
93 SIVASANKARI 50 56 150 24.8889 1 15067666 134/86 99 NS 82 124 73 B3 T4 R1 100 70 100/70 89 123/84 73 112/76 71
94 MALA 51 52 152 22.5069 1 22500301 144/74 98 NS 70 119 68 B3 T4 R1 109 78 126/76 80 120/76 78 112/56 67
95 MINI 52 53 154 22.3478 1 22180993 122/68 87 DEX 0.5 mcg/Kg78 132 67 B3 T4 R4 98 68 100/67 60 98/72 60 M6 111/77 50
96 KALAVATHY 54 53 155 22.0604 1 20859793 122/78 74 DEX 0.5 mcg/Kg80 140 92 B3 T4 R4 99 67 128/88 68 100/78 56 90/56 58
97 SHAHEEN BEGUM55 54 156 22.1893 1 10331987 120/78 65 NS 65 98 78 M6 B3 T4 R1 90 78 90/78 70 M6 100/68 67 100/76 70
98 GEETHA 56 57 153 24.3496 1 14292770 144/89 66 NS 76 109 87 B3 T4 R1 92 68 98/78 67 110/67 76 98/87 78
99 CHIMRA 54 56 154 23.6128 1 13335215 140/80 68 DEX 0.5 mcg/Kg57 108 60 M6 B3 T4 R3 100 89 100/89 56 A0.6 100/80 50 A0.6 100/78 56
100 SAGAYAMARY 51 52 152 22.5069 1 16754259 136/84 90 NS 78 110 78 B3 T4 R1 109 78 109/78 69 98/68 76 M6 100/70 78
                                                        20 MIN                                                      40 MIN 60MIN
DRUG MOTORSENSORYSEDATIONBP HR DRUG MOTOR SENSORYSEDATIONBP HR DRUG MOTORSENSORYSEDATIONBP HR DRUG MOTORSENSORYSEDATIONBP HR DRUGMOTOR SENSORYSEDATIONBP HR DRUG MOTORSENSORYSEDATION
110/87 87 122/78 70 132/86 79 B3 T8 R1 110/70 88 B2 T10 R1 112/67 78 B2 T10 R1
M6 110/78 88 112/89 68 110/65 65 B2 T8 R1 128/87 87 B2 T10 R1 112/87 87 B2 T12 R1
A0.6 100/68 60 100/68 60 B3 T4 R3 122/78 50 A0.6 B3 T4 R3 130/80 60 B3 T6 R3 110/78 60 B3 T6 R2
M6 89/56 52 M6 110/78 62 B3 T4 R3 112/67 58 B3 T6 R3 100/78 62 B3 T6 R3 122/82 66 B2 T8 R2
111/87 67 12O/80 70 B3 T6 R1 113/59 67 B3 T8 R1 110/88 77 B3 T10 R1 138/78 78 B2 T12 R1
100/789 78 108/78 68 B3 T4 R1 100/76 77 B3 T8 R1 132/86 77 B3 T10 R1 123/68 79 B2 T12 R1
A0.6 112/67 56 128/86 60 B3 T4 R4 98/78 65 B3 T4 R3 110/65 62 B3 T6 R3 147/98 67 B3 T6 R3
113/78 65 106/68 68 B3 T4 R1 102/70 78 B3 T8 R1 122/78 75 B2 T10 R1 120/80 76 B2 T12 R1
M6 114/69 60 100/76 65 B3 T6 R4 100/70 56 B3 T6 R4 112/67 57 B3 T6 R3 12O/78 50 A0.6 B3 T6 R3
112/56 59 98/67 59 B3 T6 R4 102/76 58 B3 T4 R3 113/59 58 B3 T6 R3 112/80 58 B3 T8 R3
122/78 87 110/87 77 B3 T6 R1 104/67 77 B3 T8 R1 100/76 69 B2 T10 R1 110/78 67 B2 T12 R1
100/76 67 110/80 56 B3 T6 R1 122/78 54 B2 T8 R1 109/78 57 B2 T8 R1 132/87 60 B2 T10 R1
93/58 69 M6 100/68 68 99/70 50 A0.6 B3 T6 R3 100/68 77 B3 T8 R2 110/76 62 B3 T8 R1
M6 89/56 52 M6 110/78 62 B3 T4 R3 112/67 58 B3 T6 R3 100/78 62 B3 T6 R3 122/82 66 B2 T8 R2
111/87 67 12O/80 70 B3 T6 R1 113/59 67 B3 T8 R1 110/88 77 B3 T10 R1 138/78 78 B2 T12 R1
100/789 78 108/78 68 B3 T4 R1 100/76 77 B3 T8 R1 132/86 77 B3 T10 R1 123/68 79 B2 T12 R1
A0.6 112/67 56 128/86 60 B3 T4 R4 98/78 65 B3 T4 R3 110/65 62 B3 T6 R3 147/98 67 B3 T6 R3
113/78 65 106/68 68 B3 T4 R1 102/70 78 B3 T8 R1 122/78 75 B2 T10 R1 120/80 76 B2 T12 R1
M6 114/69 60 100/76 65 B3 T6 R4 100/70 56 B3 T6 R4 112/67 57 B3 T6 R3 12O/78 50 A0.6 B3 T6 R3
112/56 59 98/67 59 B3 T6 R4 102/76 58 B3 T4 R3 113/59 58 B3 T6 R3 112/80 58 B3 T8 R3
122/78 87 110/87 77 B3 T6 R1 104/67 77 B3 T8 R1 100/76 69 B2 T10 R1 110/78 67 B2 T12 R1
100/76 67 110/80 56 B3 T6 R1 122/78 54 B2 T8 R1 109/78 57 B2 T8 R1 132/87 60 B2 T10 R1
93/58 69 M6 100/68 68 99/70 50 A0.6 B3 T6 R3 100/68 77 B3 T8 R2 110/76 62 B3 T8 R1
100/76 67 110/80 76 B3 T6 R1 122/78 78 B2 T8 R1 109/78 81 B2 T10 R1 132/87 71 B2 T10 R1
98/67 78 122/90 78 124/78 80 B2 T8 R1 112/87 80 B2 T10 R1 120/80 77 B1 T10 R1
110/87 87 122/78 70 132/86 79 B3 T8 R1 110/70 88 B2 T10 R1 112/67 78 B2 T10 R1
M6 110/78 88 112/89 68 110/65 65 B2 T8 R1 128/87 87 B2 T10 R1 112/87 87 B2 T12 R1
A0.6 100/68 60 100/68 60 B3 T4 R3 122/78 50 A0.6 B3 T4 R3 130/80 60 B3 T6 R3 110/78 60 B3 T6 R2
M6 89/56 52 M6 110/78 62 B3 T4 R3 112/67 58 B3 T6 R3 100/78 62 B3 T6 R3 122/82 66 B2 T8 R2
111/87 67 12O/80 70 B3 T6 R1 113/59 67 B3 T8 R1 110/88 77 B3 T10 R1 138/78 78 B2 T12 R1
100/789 78 108/78 68 B3 T4 R1 100/76 77 B3 T8 R1 132/86 77 B3 T10 R1 123/68 79 B2 T12 R1
A0.6 112/67 56 128/86 60 B3 T4 R4 98/78 65 B3 T4 R3 110/65 62 B3 T6 R3 147/98 67 B3 T6 R3
113/78 65 106/68 68 B3 T4 R1 102/70 78 B3 T8 R1 122/78 75 B2 T10 R1 120/80 76 B2 T12 R1
                                                                120 MIN                                                                 140 MIN                        160 MIN                                                100 MIN60MIN                                                                       80 MIN
BP HR DRUG MOTOR SEDATIONBP HR DRUGMOTOR SENSORYSEDATIONBP HR DRUG MOTOR SENSORY SEDATIONBP HR DRUGMOTOR SENSORY SEDATIONBP HR DRUGMOTORSENSORYSEDATIONBP HR SPO2
110/78 77 B2 L2 R1 136/84 71 B1 S2 R1 122/78 89 B0 S2 R1 135/87 80 B0 S2 R1 138/89 87 B0 S2 R1
100/67 78 B1 L2 R1 146/80 75 B0 S2 R1 124/78 87 B0 S2 R1 143/87 85 B0 S2 R1 122/78 89 B0 S2 R1
98/76 77 A0.6 B3 T8 R2 130/92 56 B2 T10 R2 136/84 98 B1 L3 R1 136/86 71 B0 S2 R1 124/78 78 B0 S2 R1
132/84 61 A0.6 B2 T10 R2 130/76 60 B1 T10 R1 134/72 77 B0 L3 R1 145/78 92 B0 S2 R1 136/84 78 B0 S2 R1
132/80 53 B1 L2 R1 128/67 77 B0 S2 R1 132/80 78 B0 L3 R1 128/89 80 B0 S2 R1 132/76 80 B0 S2 R1
109/78 56 B1 L2 R1` 147/98 89 B0 S2 R1 132/80 70 B0 S1 R1 130/80 82 B0 S2 R1 132/76 89 B0 S2 R1
112/87 65 B3 T8 R3 120/80 66 B2 T10 R2 109/78 67 B2 T12 R2 140/88 69 B1 T12 R2 138/89 69 B0 S2 R1
110/70 76 B1 L2 R1 12O/78 76 B0 L4 R1 112/87 80 B0 S2 R1 145/95 98 B0 S2 R1 122/78 78 B0 S2 R1
128/87 63 B2 T8 R3 112/80 67 B2 T10 R3 110/70 62 B2 T12 R3 132/76 65 B1 T12 R2 124/78 77  B0 S2 R1
130/80 51 A0.6 B2 T8 R3 100/60 62 B2 T10 R2 128/87 62 B2 T12 R2 138/89 70 B1 L2 R2 136/84 71 B0 S2 R1
100/78 76 B1 L2 R1 98/67 89 B0 L4 R1 130/80 89 B0 S1 R1 122/78 89 B0 S2 R1 146/80 53 B0 S2 R1
12O/78 65 B2 T12 R1 122/78 66 B1 L2 R1 132/76 68 B1 S1 R1 134/87 69 BO S2 R1 145/95 56 B0 S2 R1
124/78 67 B2 T8 R1 112/76 67 B1 T10 R1 123/89 77 B0 L1 R1 132/76 76 B0 L3 R1 144/86 56 B0 S2 R1
132/84 61 A0.6 B2 T10 R2 130/76 60 B1 T10 R1 134/72 77 B0 L3 R1 145/78 92 B0 S2 R1 136/84 78 B0 S2 R1
132/80 53 B1 L2 R1 128/67 77 B0 S2 R1 132/80 78 B0 L3 R1 128/89 80 B0 S2 R1 132/76 80 B0 S2 R1
109/78 56 B1 L2 R1` 147/98 89 B0 S2 R1 132/80 70 B0 S1 R1 130/80 82 B0 S2 R1 132/76 89 B0 S2 R1
112/87 65 B3 T8 R3 120/80 66 B2 T10 R2 109/78 67 B2 T12 R2 140/88 69 B1 T12 R2 138/89 69 B0 S2 R1
110/70 76 B1 L2 R1 12O/78 76 B0 L4 R1 112/87 80 B0 S2 R1 145/95 98 B0 S2 R1 122/78 78 B0 S2 R1
128/87 63 B2 T8 R3 112/80 67 B2 T10 R3 110/70 62 B2 T12 R3 132/76 65 B1 T12 R2 124/78 77  B0 S2 R1
130/80 51 A0.6 B2 T8 R3 100/60 62 B2 T10 R2 128/87 62 B2 T12 R2 138/89 70 B1 L2 R2 136/84 71 B0 S2 R1
100/78 76 B1 L2 R1 98/67 89 B0 L4 R1 130/80 89 B0 S1 R1 122/78 89 B0 S2 R1 146/80 53 B0 S2 R1
12O/78 65 B2 T12 R1 122/78 66 B1 L2 R1 132/76 68 B1 S1 R1 134/87 69 BO S2 R1 145/95 56 B0 S2 R1
124/78 67 B2 T8 R1 112/76 67 B1 T10 R1 123/89 77 B0 L1 R1 132/76 76 B0 L3 R1 144/86 56 B0 S2 R1
12O/78 76 B2 L2 R1 122/78 78 B1 S1 R1 132/76 98 B1 S2 R1 134/87 88 BO S2 R1 145/95 90 B0 S2 R1
112/80 78 B1 L2 R1 124/78 77 B0 S2 R1 138/89 87 B0 S2 R1 134/78 98 B0 S2 R1 132/76 98 B0 S2 R1
110/78 77 B2 L2 R1 136/84 71 B1 S2 R1 122/78 89 B0 S2 R1 135/87 80 B0 S2 R1 138/89 87 B0 S2 R1
100/67 78 B1 L2 R1 146/80 75 B0 S2 R1 124/78 87 B0 S2 R1 143/87 85 B0 S2 R1 122/78 89 B0 S2 R1
98/76 77 A0.6 B3 T8 R2 130/92 56 B2 T10 R2 136/84 98 B1 L3 R1 136/86 71 B0 S2 R1 124/78 78 B0 S2 R1
132/84 61 A0.6 B2 T10 R2 130/76 60 B1 T10 R1 134/72 77 B0 L3 R1 145/78 92 B0 S2 R1 136/84 78 B0 S2 R1
132/80 53 B1 L2 R1 128/67 77 B0 S2 R1 132/80 78 B0 L3 R1 128/89 80 B0 S2 R1 132/76 80 B0 S2 R1
109/78 56 B1 L2 R1` 147/98 89 B0 S2 R1 132/80 70 B0 S1 R1 130/80 82 B0 S2 R1 132/76 89 B0 S2 R1
112/87 65 B3 T8 R3 120/80 66 B2 T10 R2 109/78 67 B2 T12 R2 140/88 69 B1 T12 R2 138/89 69 B0 S2 R1
110/70 76 B1 L2 R1 12O/78 76 B0 L4 R1 112/87 80 B0 S2 R1 145/95 98 B0 S2 R1 122/78 78 B0 S2 R1
                                                               240 MIN                                                                     260 MIN                                                                  280 MIN                                          180 MIN                                                                      200 MIN                                                                     220 MIN
300 MIN
DRUG MOTOR SENSORY SEDATION BP HR SPO2 DRUG MOTOR SENSORY SEDATION BP HR SPO2 DRUG MOTOR SENSORY SEDATION BP HR SPO2 DRUG MOTOR SENSORY
                                                                  280 MIN
SEDATION
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PATIENT CONSENT FORM
Study title
Effect of intravenous dexmedetomidine on prolonging spinal anesthesia, a randomized
controlled study
Study centre  : ESI – PGIMSR, K.K.NAGAR, CHENNAI -78
Participant name :                                                Age:                         Sex:
I confirm that I have understood the purpose of procedure for the above study . I have the
opportunity to ask the question and all my questions and doubts have been answered to my
satisfaction.
I have been explained about the pitfall in the procedure.  I have been explained about the
safety, advantage and disadvantage of the technique. I understand that my participation in the study
is voluntary and that I am free to withdraw at anytime without giving any reason.
I understand that investigator, regulatory authorities and the ethics committee will not need
my permission to look at my health records both in respect to current study and any further research
that may be conducted in relation to it, even if I withdraw from the study . I understand that my
identity will not be revealed in any information released to third parties or published , unless as
required under the law . I agree not to restrict the use of any data or results that arise from the study.
I understand that  that I will receive drugs intravenously to prolong spinal anesthesia. I will
receive Inj. Dexmedetomidine ,intravenously .  I have been explained that the anesthetic technique is
a standard and approved technique. I have been explained that the drug will cause sleep and a
reduction in heart rate. This may help in future research in the field of anesthesia. I consent to
undergo this procedure
Insurance No:
Date:                                                                                             Signature / thumb impression of
                                                                                                                  Patient
B´ÄUPõÚ J¨¦uÀ £iÁ®
PROFORMA
Name of the patient:
                                                                    Age:
Sex Wt:
Insurance No: OT:
Diagnosis: Duration of Procedure:
Surgeon: Anaesthetist
PREOPERATIVE DETAILS
ASA Grade Remarks:
vitals
SIGNATURE OF INVESTIGATOR             SIGNATURE OF THE PARTICIPANT
 WITNESS:
BP Pulse
rate
Resp.
rate
SpO2 Temp ECG Xray
Hb RBS RFT LFT Others
